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General introduction 
In vitro fertilization and cmblYo transfer (IVFIET), the culture of aspirated aGcytcs and spermato-
zoa in the JaboratOly follO\ved by transccrvicai embryo transfer, ,vas originally used as a treatment 
for infertility resulting from impaired fUllction of the fallopian tubes. A few years after the intro-
duction of IVF/ET the indications for treatment included infertility caused by endometriosis, male 
factors, ovulation disorders and unexplained infertility (1). Although IVF has now become an 
accepted treatment for infertility, there are still several contentiolls issues in the application of 
assisted reproductive technologies (ART) (2). It has been argued by World Health Organization 
authorities that IVF benefits only a small propmtion of infertile couples, that it is expensive, and 
that it has serious health risks (3). In a WHO repOli from the Regional Office for Europe it was 
suggested that eligibility for IVF should be limited to wOlllen under 40 years of age, that the nUIll-
ber of treatment cycles per woman should be limited, and that no more than three embryos should 
be transferred per treatment cycle (4). The increased ineidencc of triplet and higher-order preg-
nancies caused by ovulation induction and ART (5, 6), its associated increased medical risks (7) 
and high costs (8) have been reported. Apparently, sOllle health authorities still consider ART 
controversial. This critical approach stresses the need for IVF programmes to raise their level of 
accountability. 
In this thesis, the logistical and some clinical aspects of the IVF treatment as carried out in the 
transport IVF programme at the Zuiderziekenhuis, Rotterdam, in collaboration with the Univer-
sity Hospital Dijkzigt, Rotterdam, are analyzed. The aims of this thesis are: to determine the effi-
cacy of a decentralized IVF programme with transport and satellite clinics, to fmiher develop cri-
teria for acceptance of patients, to develop a safer treatment strategy avoiding high-order preg-
nancies, and, where possible, to touch upon the issues mentioned above. 
Logistical aspects of in vitro fertilization treatment 
The argument that IVF benefits only a small proportion of infertile women (3) is not valid in The 
Netherlands. Only very few women do not benefit from insurance, and in practically all cases the 
cost of the fIrst three IVF attempts is paid for by health insurance. Consequently, all patients with 
an indication for IVF can be offered three IVF attempts without major fInancial restrictions. The 
number of IVF laboratories in The Netherlands has been limited to 12 by govelllll1ent regulation. 
Initially, this led to long waiting lists for patients with an indication for IVF. Since the capacity of 
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the lYF laboratOlY is usually larger than the treatment capacity of the clinical team, transport IYF, 
with transport of aspirated oocytes from a transport rVF clinic to a central IYF laboratOlY was 
introduced to enhance the availability of IVI' treatment to the public (9, 10). The logistical or-
ganization of the programme at the Zuiderziekenhuis was further developed by the introduction of 
satellite clinics where monitoring of the controlled ovarian hyperstimnlation (COH) takes places. 
The cooperation between the transport centre and the satellite clinics offers the patients consider-
able advantages in tenllS of convenience, travelling time and expenses. In the first chapter of this 
thesis the results of this decentralized IYF programme are evaluated. Time spent on IYF treatment 
could be used productively in other endeavors and should be considered a component of eco-
nomic costs. These indirect costs have been estimated to add $880 to the cost of an average cycle 
(Il). Therefore, further simplification of the logistical organization by using a minimal monitor-
ing schedule during COR makes an rVF programme even more accessible to patients, and lowers 
treatment costs even further. To achieve this, a minimal monitoring schedule for COR was intro-
duced in the transport IVI' programme at the Zuiderziekenhuis. The feasibility of tlIis schedule is 
evaluated in chapter 2. Furthermore, the literature is reviewed with respect to the logistical ad-
vantages of the use of gonadotrophin-releasing hormone agonists (GnRH-a) in IVF treatment, and 
the experience with GnRH-a in the transport IVF centre is presented in chapter 3 . 
Aspects of patient selection for in vitro fertilization 
The decrease in fecundity with rising age is generally known. Schwartz and Mayaux (12) reported 
evidence for a decrease in fecundity after the age of 30. In IVI' treatment the age of the female 
partner has been found to be an imp0l1ant detenl1inant of success. Consequently, this has Jed to 
age limits for acceptance of patients in many IVF programmes. In the Netherlands the general 
opinion in IVF programmes is that patients aged 40 years and older should not be offered treat-
ment. A WHO report (4) suggests to exclude patients aged over 40 years. However, the validity of 
such strict age limits can be questioned. Prestimulation tests proved to be better predictors of an 
individual patient's IVI' perfonnance than age (13-15). Chapter 4 is a review of the literature on 
the relation between age and IVI' results. Chapter 5 is a study carried out to detenuine whether 
age or the ovarian response to COB is the better predictor for successful IYF treatment after the 
age of40. 
:tvlale subfertility has become an accepted indication for IVF. However, in couples with an ex-
treme male factor, semen parameters can be unacceptable for IVF because of expected Jow fertili-
zation rates. For these couples intracytoplasmic spellli injection (ICSI) has proved to be an effec-
10 
tive method of assisted fertilization (16) with a low fertilization failure mte (17). Failed feIiiliza-
tion in standard IVF is another reason to select patients for IeS!. The definition of failed fertiliza-
tion used by Van Stcirteghem et al. (18) was: the total absence of oocytes with two pronuclei 16-
18 hours after insemination of a sufficient number of oocytes, or a fertilization rate of < 5% in 
several treatment cycles. This definition raises questions. 'Vhen do we speak of a sufficient num-
ber of oocytes? \Vhy should the fertilization rate be < 5%, or even ~ 10% as mentioned by the 
same group (19) in a later publication? Preferably, IVF programmes should develop their own 
criteria for failed fertilization and assess the recurrence rate of this frustrating event in their own 
population. In the patient population of the transport IYF centre the treatment prognosis after poor 
fertilization in the first IVF cycle is assessed and recommendations for subsequent cycles are 
made in chapter 6. 
Procedure-related clinical complications of IVF 
In vitro fertilization is an elective procedure, and therefore the procedure-related complications 
arc always iatrogenic. Serious complications arc reported to occur infrequently, but in cases of the 
severe form of ovarian hyperstimuiation syndrome (OHSS) secondmy complications can lead to 
life-threatening conditions. Although the numerous publications on this subject give an impres-
sion of the frequency of occunence of complications, hardly any reports exist about the incidence 
of the various complications in one programme. Berg and Lundkvist (20) reported on the clinical 
complications in 12 IYF clinics in Nordic countdes. It is necessaty to infol1n patients about the 
occurrence of complications in the very IVF programme they afe about to join. In chapter 7 the 
incidence of the various clinical complications in the transport IVF programme at the Zuiderz-
iekenhuis is reported, and the literature on this subject is reviewed. 
One of the most controversial issues in IVF is the occurrence of triplets and higher-order preg-
nancies after replacement of three or more emblYos. About 70% of triplet pregnancies occurring 
nowadays result from ovulation induction or ART (5, 6). The high costs (8) and the increased 
medical risks (7, 21) have bcen extensively described. The nccessity of avoidance of triplets and 
higher-order pregnancies in IVF programmes has been stressed (8). Several authors suggested a 
limitation of the number of embryos to be replaced to achieve this (22, 23). Despite these recom-
mendations the incidence of triplet pregnancies after IYF does not appear to decrease (24, 25), 
and replacement of even six or more embryos in patients with repeated previous IVF failures has 
been proposed (26). There are several explanations for this approach. In the first place, IVF pro-
grammes are mainly judged by the prcgnancy rates obtained, and not by the frequency of proce-
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dure-reIated complications. In some programmes this will lead to replacement of high numbers of 
emblYos. Secondly, the increased morbidity and mortality of triplet and quadruplet pregnancies, 
and the psychological stress and social consequences for the parents might be underestimated, or 
seen as acceptable risks. Tn the third place, the availability of selective embtyo reduction as a 
method to reduce high-order pregnancies to twins or even singletons, is probably seen by some as 
the solution for the occurrence of triplets and higher-order pregnancies. Chapter 8 is an analysis of 
the fi:equellcy of occunence and of the obstetric outcome of triplet pregnancies in the transport 
IVF programme. This study was calTied Ollt to investigate whether triplet pregnancies should be 
completely prevented. 
The expression of success rates in IVF 
Before starting IVF treatment, couples need to be provided with adequate information about their 
chances to achieve a pregnancy. In the United Kingdom licensed IVF and donor insemination 
clinics therefore have a statutory duty to provide relevant infolUmtion to patients before offering 
treatment (Human Fertilisation and Emblyology Act 1990). In 1995 the "Patient's Guide to Donor 
Insemination and IVF Clinics" with the success rates of licensed lVF clinics was published (27). 
Using success rates for pre-treatment counselling should be done with care rates are not applica-
ble to individuals and a possible reduction in pregnancy rate in successive cycles should be COI1-
sidered. This phenomenon has been described by several authors (28, 29), and is explained by 
heterogeneity of the popUlation in terms of fecundity rate .. Moreover, when cumulative pregnancy 
rates are used to express success, lllany programmes assume that patients who leave the pro-
gramme after a h1iled attempt would have had the same probability of a pregnancy as those who 
continued. "'hen patients drop out because of poor performance, e.g. few oocytes retrieved or 
failed fertilization, this assumption is of course incorrect. Consequently, the calculated cumulative 
pregnancy rate will be too high. In chapter 9 the cumulative pregnancy rate in the transport IVF 
programme is analyzed, all~ the validity of this rate is tested by determining whether there is a 
selective drop-out of patients with poor treatment prognosis. 
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Chapter 1 
Results of decentralized IVF treatment with transport 
and satellite clinics 
HUll/an Reproduction 1995; I 0:563-7. 
Jan Roest', Arie VerhocfP, Matt van Lentl, Gerda J. Huisman2, Gerard H. Zeilmaker3 
1 Department of Obstetrics and Gynaecology, Zuiderziekcllhuis, Rotterdam, The Netherlands. 
lIVF laboratOlY, University Hospital Dijkzigt, Rotterdam. 3Dcpartment of Endocrinology and Re-
production, Erasmus University, Rotterdam. 
SUllllllary 
The results of in vitro fertilization (IVF) treatments, carried out in a university IYF centre, arc 
compared \vith those obtained following 15-40 minutes transportation of oocytcs from a transport 
IVF clinic to the central IVF laboratory of the university centre. Moreover, treatment results fol-
lowing monitoring of ovarian hyperstinmlatioll in satellite clinics, combined with ovum retrieval 
at the transport clinic and transport of oocytes to the central IVF laboratOlY, are described. 
In a total of 5540 IVF treatment cycles, 24-26 percent of viable pregnancies per embtyo trans-
fer were found in the three groups. Comparison of results, obtained with the three different treat-
ment modalities, shmvs no negative influences of transporting oocytes from transport clinic to 
IVF laboratOlY and of monitoring ovarian hyperstimulation in satellite clinics. It is concluded that 
decentralization of the clinical phase of IVF treatment is possible. This leads to a more optimal 
use of existing laboratOlY facilities in large urban areas. It is stressed that efficient communication 
behveen satellite clinic, trallspOit clinic and IVF laboratOlY is necessmy for a decentralized IVF 
programme. To obtain good quality assurance, both the satellite clinic and the transport clinic 
must adhere to the same protocol. 
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Introduction 
In The Netherlands the number of in vitro fertilization (JVF) laboratories has been limited to 12 
by government regulation. Because the capacity of the IVF laboratory at IVF centres is usually 
larger than the treatment capacity of the clinical team, transport lVF, with carriage of aspirated 
oocytes from a transport IVF clinic to a central IVF laboratory, was introduced in 1984 (1-3). A 
transport IVF clinic is a facility where the complete clinical phase of the IVF treatment, including 
oocyte aspiration and follmv-up after emblYo transfer, can take place. The laboratory phase and 
embryo transfer are carried out at a different location. In a prospective pilot Shldy, the results of 
transport lVF treatment cycles were compared with thosc in the central clinic (2). Transport of 
oocytes over 30-60 minutes proved to be possible without loss of fertilizability. The transport IVF 
programme at the Zuiderziekcnhuis, Rotterdam, started in 19R4. Satellite clinics, \vhere monitor-
ing of ovarian stimulation takes place according to the protocol of thc transport clinic, were added 
to the programme in 1988 so as to limit travelling time and inconvenience for the patients. 
A rctrospective study with the objective of assessing thc feasibility of large scale transpOli and 
satellite-transport IVF was carried out. The results of a 5 year period were analyzed and com-
pared with concurrent results obtained in thc central IVF unit at the University Hospital of RoUer-
dam. The results of cycles monitored at satellite clinics were comparcd with non-satellite moni-
tored cycles. The results of the six different satellite clinics were compared to investigatc if any 
variability could be found for the outcome of IVF treatment after monitoring of ovarian stiullIla-
tion at these clinics . 
. Materials and methods 
Three different treatment modalities were compared in this study. One group of patients (3333 
cycles) reeicved the clinical and the laboratory phases of IVF treatment at one location, the Uni-
versity Hospital of Rotterdam. A second group (2207 cycles) was treated at marc than one loca-
tion, recieving clinical treatment, including ovum retrieval, in the transport clinic, followcd by 
carriage of the ooeytes to the IVF laboratory at the University Hospital where the laboratory 
phase, including cmbryo transfer, took place. The transport clinic patient group was divided into 
two subgroups: 1637 cycles stimulated and monitored during ovarian stimulation at the transport 
clinic, and 570 cycles stimulated and monitored at one of the SLX satellite clinics participating in 
the programme. Patients travelled from the satellite clinics to the transport clinic for ovum re-
trieval. For these three treatment modalities the same IVF laboratOlY £1cilities were used. 
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Patient selection for the transport 1V1' programme was carried out at the Zuiderziekenhuis, the 
transport clinic. All patients were <43 years of agc and were are accepted for the programme 
when they had a clear indication for IVF treatment and after serological tests (HBsAG, syphilis, 
human imlllunodeficiency virus) and routine physical examination. Ovarian stimulation consisted 
of human menopausal gonadotrophin (HMG) 150-450 IV i.m.lday (Humegon'; Organon, Oss, 
The Netherlands), depending on age and IVF indication, starting on cycle day 3. Since the gradual 
introduction of gonadotropin-releasing hOl1none agonists, in the period 1989-1991, the short £lare-
up regime was used in most cases, starting on cycle day 1 until the day of human chorionic go-
nadotrophin (HCG) injection. Plasma estradiol measurements were not eanied out in vie\" of the 
results obtained at the central lInit by Leerentveld et al. (4). iVionitoring of follicle growth and 
endometrium development was performed by vaginal ultrasound measurements only. Oocyte 
retrieval was planned 35 hours after i.m. injection of 10,000 IU HCG (Pregnyl'; Organon) on the 
day the leading follicles reach a diameter of 18-20 mm, measured in three dimensions. Follicle 
aspiration was canied out by vaginal puncture under local anaesthesia. Oocyte isolation from the 
aspirates and subsequent laboratory procedures including emblYo transfer \"ere performed at the 
central 1VF laboratory at the University Hospital of Rotterdam. 
The distance between the transport clinic and_ the IVF laboratory was 7 km and the travelling 
time by car was 15-40 minutes. Oocytes were transported in their own follicular fluid in labelled 
vials placed in an insulated box with a preheated (35" C) block of aluminium. In this box the 
temperature remained constant (within 0.3° C) for at least one hour at an environmental tem-
perature of 4° C. Regular tests of isothennic capacity were carried out. The box was carried to the 
central laboratory by the patient's partner. Semen was produced in the central laboratory. The 
laboratory procedure was recently described by Huisman et al. (5). 
Luteal support was given with 1,500 lU HCG on the day of ovum retrieval (day 0) and on 
days 3, 6 and 9. \Vhen .2:'.15 follicles ,,,ere retrieved, progesteronc (200 mg vaginally twice daily; 
Progestmrf"; Organon) \vas prescribed for 15 days. In these cases HCG was withheld. 
The number of emblYos rcplaced (to a maximum of [our) depended on the patient's age and 
the quality of the embryos. Patients <35 years of age ,,,ere asked to consider replacement of not 
more than two embryos so as to prevent a triplet pregnancy. The final advice on the number of 
embryos to be replaced was given by the IVF laboratory staff. 
A clinical pregnancy was dcfincd by a positive urinmy test 18 days after oocyte retrieval com-
bined with the finding of a gestational sac two weeks later. A pregnancy was considered to be 
viable when fetal heart motion had been observed after seven weeks of amcnorrhoea. 
Satellite treatment was added to the transport IVF programme in 1988. Six clinics, at 100-200 
km distance from Rotterdam, started to monitor ovarian stimulation for their own patients by 
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transvaginal ultrasound only. All decisions concelllmg patient selection, ovarian stimulation, 
monitoring protocol, timing of HCG injection and ovum retrieval were made according to the 
protocol of the transport clinic. Regular consultation with the transport clinic took place during 
ovarian stimulation. The satellite clinic contacted the transport clinic when follicle development 
allowed the timing of oocyte aspiration. A precise description of the number and size of follicles 
found during monitoring \vas given by the satellite physician. The day ovum retrieval was 
planned, the patient travelled to the transport clinic; oocyte aspiration with transportation of the 
oocytes to thc central laboratory followed. In general, patients travelled to Rottcrdam only thrcc 
times: for intake and screening procedures, for follicle aspiration and for emblYo transfer. During 
subsequent cycles only two visits were necessary. 
A clinic WaS allowed to fUllctioll as a satellite clinic after adequate training of the staff mem-
bers involved in ovarian stimulation and monitoring. At two satellite clinics the staff members 
involved in IVF treatment previously participated ih the IVF programme at the transport clinic for 
one year. Staff members at the other satellite clinics were offered 1 week of individual training at 
the transport clinic. Satellite physicians were provided with a detailed protocol for ovarian hyper-
stimulation and monitoring. An oocyte recovery rate of 70-80% of follicles reported to have a 
diameter ~l 0 llllll was considered acceptable. "'hen this recovelY rate was not achieved, the 
monitoring physician was contacted and the case discussed. The IVF results of each satellite 
clinic were evaluated on a regular basis and compared with the results of the transport clinic. Staff 
members at the transport clinic \vere expected to cany out a minimum number of fifty follicle 
aspirations a year for good quality assurance. No continuous record was kept of the oocyte re-
trieval rate, but regular random samples provided information on the individual physician's per-
formance. 
For statistical analysis, Student's t-test was used for the difference between two means and X1 
test was used to compare the frequencies of observations. P < 0.05 was taken as the level of sig-
nificance. 
Results 
The results of 2207 IVF treatments at the transport IVF clinic were compared with 3333 IVF 
treatments at the University Hospital of Rotterdam during the period Janumy 1989 - December 
1993. The two patient groups showed a significant difference in mean age (±SD): 33.1 ± 4.3 years 
and 34.0 ± 4.1 years respectively (P < 0.01). However, this difference of 0.9 years was small and 
had no clinical significance for the outcome of IVF treatment. The distribution of indications for 
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IVF treatment is shown in table 1. For the two main indications there appeared to be a significant 
diffcrence in frequcncy. Tubal dysfunction was more often found in the University Hospital 
group (P < 0.01), while male subfertility was more frequent in the transport clinic group (P < 
0.01). 
The main results of IYF treatment at the two locations are sho\\,11 in table 2. The mean num-
bers of ooeytes and embryos per ovum retrieval differed significantly (P < 0.0 I) between trans-
port clinic and University Hospital. The transport clinic had fewer embryo transfers (P < 0.01). A 
significantly higher number of embryos was transferred in the University Hospital group (P < 
0.01), probably due to advice given more frequently to patients at the transport clinic to have only 
two embryos replaced. As a result, more clyopreservations (P < 0.01) per oocyte retrieval were 
seen in the transport clinic population. The percentages of clinical and viable pregnancies were 
similar in both groups. Ivfore multiple pregnancies (P < 0.01) were seen in the University Hospi-
tal group. The embtyo implantation rates \vere similar in both groups. 
Table 1. [ndieations for NF in Transport Clinic and University Hospital 
Transport Clinic (%) University Hospital (%) 
(n ~ 2207) (n ~ 3333) 
Tubal dysfunction * 46 52 
Endometriosis 7 4 
Male subfertility * 23 16 
Idiopathic 19 22 
Rest and combinations 5 6 
*Differences within rows significant (P < 0.01) 
Starting in 1988, six satellite clinics monitored the ovarian stimulation for their own patients. 
As shown in table 3, the number of patients monitored at thc satellite clinics increased since the 
satellite programme started. 
The results of 1637 cycles monitored at the transport centre were compared with 570 cycles 
monitored at satellite clinics. A statistically significant difference was found between the two pa-
tient groups with regard to mean age (± SD): 33.3 ± 4.3 years and 32.6 ± 4.0 years respectively ( 
P < 0.01). The indications for IVF in the two patient groups are shown in table 4. A statistically 
significant difference was found in the frequencies of tubal dysfunction (P < 0.02), and idiopathic 
infertility (P < 0.01). 
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The results of IVF treatment cycles monitored at the transport clinic, compared with the re-
sults of cycles monitored at the six satellite clinics, are shown in tablc 5. Statistically sigificant 
differences between transport and sa.teIlitc clinics \vere found for the mean numbers of ooeytcs 
and embryos per retrieval (P < 0.01), and for thc number of emblYo transfers (P < 0.01). The 
mean number of emblYos replaced was the same. The difference for clyopreservations was not 
significant. The percentages of clinical and viable pregnancies did not differ. The differences in 
percentage multiple pregnancies and in implantation rate were not significant. The incidence of 
severe ovarian hyperstimulatioll syndrome (OHSS), grade 5 or 6 according to the classification by 
Golan et a!. (6), for the transport and satellite clinics population did not differ. 
Table 2. Results offVF Treatment in Transport Clinic and in University Hospital. 
Transport Clinic University Hospital 
Oocyte retrievals 2207 3333 
Oocytes per retrieval (mcan ± SO) • 9.7 ± 7.5 9.3± 6.5 
Fertilization rate (%) 50.5 48.4 
EmblYos per retrieval (mean ± SO) * 4.9 ± 5.1 4.5± 4.7 
Embryo transfcrs· (% t) 1786 (80.9) 2824 (84.8) 
Embryos replaced (mean ± SO) • 2.6 ± 0.9 2.8± 1.0 
Clyopreservations ~ (% t) 642 (29. I) 845 (25.4) 
Clinical pregnancies (% §) 512 (28.7) 810 (28.7) 
Multiple pregnancies * (% II) 124 (24) 252 (31) 
Twins (% III 106 (20) 194 (24) 
Triplets (% III 18 (4) 56 (7) 
Quadruplets (% II) 2 (0.2) 
EmblYo implantation rate (%) 14.0 14.1 
Viable pregnancies (% §) 434 (24.3) 677 (24.0) 
* Differences within rows significant (P < 0.01). § Percentage per emblYo transfer. 
t Percentage per oocyte retrieval. II Percentage per clinical 
t Data on thawillgs and clyopregnancies are pregnancy. 
not included in this table. 
The results of IVF treatment obtained after monitoring in the six different satellite clinics are 
given in table 6. In the patient group at clinic I, male subfertility (38%) was significantly more 
frequent as the indication for IVF (P < 0.01). This was associated with a significantly lower fcr-
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tilization rate (P < 0.01). Significantly less frequent male subfertility (13%) in the group at clinic 
2 (P < 0.02) was associated with a higher fertilization rate (P < 0.01). A higher emblYo implanta-
tion rate was found in the clinic I group ( P < 0.05). The differences between the six clinics for 
percentages embryo transfers, clinical pregnancies and ongoing pregnancies were not statistically 
significant. 
Table 3. Number of TranspOlt IVF Cycles Monitored at Transport Clinic and Satellite 
Clinics. 
Year 
1989 
1990 
1991 
1992 
1993 
Totalno.cycles 
229 
363 
486 
555 
574 
Values in parentheses arc percentages. 
TranspOit Clinic Satellite Clinics 
196 (86) 33 (14) 
305 (84) 58 (16) 
359 (74) 127 (26) 
391 (70) 164 (30) 
386 (67) 188 (33) 
Table 4. Indications for IVF in Transport Clinic and Satellite Clinics 
Transport Clinic (%) 
(n ~ 1637) 
Tubal dysfunction * 48 
Endometriosis 7 
Male subfertility 22 
Idiopathic t 18 
Rest and combinations 5 
* Difference within row significant (P < 0.02). 
t Difference within row significant (P < 0.01). 
Satellite Clinics (%) 
(n ~ 570) 
40 
7 
25 
23 
5 
25 
Discussion 
The results show that IVF treatment in combination \vith transport of oocytes and monitoring in a 
distant satellite clinic yields a similar percentage of viable pregnancies as compared to a complete 
treatment in one centre. The results also confinn earlier studies (1, 2, 7, 8). 
Table 5. Results of IVF Treatment in the Transport Clinic only and in Combination with 
Satellite Clinics. 
TranspOlt Clinic Satellite Clinics 
Oocyte retrievals 
Oocytes per retrieval (mean ± SD) • 
Fertilization rate (%) 
Emblyos per retrieval (mean ± SD) • 
Embryo transfers' (% 1") 
EmblYos replaced (mean ± SO) 
Cryopreservations:j: (% t) 
Clinical pregnancics (% §) 
Multiple pregnancies (% III 
Twins (% III 
Triplets(% II) 
EmblYo implantation rate (%) 
Viablc pregnancies (% §) 
Severe OHSS '1 (% t) 
• Differences within rows significant (P < 0.01). 
t Percentage per oocyte retrieval. 
t Data on thawings and cryopregnancies are 
not included in tlris table. 
1637 
9.9 ± 7.6 
51.5 
5.1 ± 5.2 
1347 (82.3) 
2.6 ± 0.9 
483 (29.5) 
386 (28.7) 
85 (22) 
73 (19) 
12 (3) 
13.6 
321 (23.8) 
13 (0.8) 
570 
9.3 ± 6.5 
48.4 
4.5 ± 4.7 
439 (77.0) 
2.6 ± 0.9 
159 (27.9) 
126 (28.7) 
39 (31.0) 
33 (26) 
6 (5) 
15.1 
113 (25.7) 
5 (0.9) 
§ Percentage per emblYo transfer . 
II Percentage per clinical pregnancy. 
~ Classification of Golan et al (6). 
The replacement of significantly fewer emblyos did not affect the percentage of clinical preg-
nancies obtained in the transpOit clinic group. In this group a statistically significant lower multi-
ple pregnancy rate was found. These findings confirm an earlier study by Staessen et al. (9). 
The maximulll duration of oocyte transpOit in this Shldy was 40 minutes. In this period the 00-
cytes did not lose their capacity to be fertilized and to develop into a viable emblYo. It is unknown 
whether transport of longer duration will yield similar results. Adequate tempera hire regulation 
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during transport must be guaranteed. The use of a preheated (35"C) aluminium block in an insu-
lated box has proved to be adequate in Qur programme. No power source is needed during transR 
Pott. In this way possible technical problems during transport are avoided. During transportation 
the aocytes remain in their OW11 follicular fluid. Apparently this fluid exerts no harmful effects on 
the oocyte. The fertilization rate reported has been influenced by the high frequency of male sub-
fertility as indication for IVF treatment. 
No negative effect on the outcome of 1 VF treatment is caused by the monitoring of ovarian 
stimulation by physicians in satellite clinics. The incidence of severe OHSS in the patient group 
stimulated and monitored at the satellite clinics is 110t increased and is comparable to incidences 
reported earlier (10, II). The use of satellite clinics in an IVF programme has been described by 
others (7, 12-14). The introduction of satellite clinics made our transport IVF programme more 
accessible to patients in other parts of the counhy. Travelling time and inconvenience for the pa-
tients are limited since the monitoring of ovarian stimulation is carried out in their local hospital 
by their own gynaecologist. \Vhen satellite physicians monitor ovarian stimulation for their own 
patients, arrangements have to be made to obtain quality assurance. Satellite physicians should be 
familiar with the technique of vaginal ultrasound measurement of follicles and follow the treat-
ment protocol of the transport clinic. The transport clinic, being responsible for the complete 
clinical phase of the IVF treatment including possible complications, should always be available 
to patients and satellite physicians for consultation, since difficulties may arise when the liability 
for mistakes during the IVF treatment has to be defined (15). The result of each ovarian stimula-
tion should be communicated to the transport clinic before oocyte retrieval is planned. Satellite 
clinics should be informed about the laboratOlY results of their own patients, and the outcome of 
the IVF treatment should be reported to the transport clinic. 
To obtain satisfaetOlY IYF results the quality of the IVF laboratory is of significant impor-
tance. Once a laboratory has obtained a consistently good pregnancy rate, it is preferable to use 
the services of this laboratOlY instead of starting a new IVF laboratOly. It seems that in large ur-
ban areas a decentralized IVF programme, with a central laboratOlY, is to be preferred above a 
programme with several small laboratories \'lith less experienced personnel. :Moreover, a decen-
tralized programme is a more cost-effective approach to large scale IVF treatment. 
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tv Table 6. Results ofIn Vitro Fertilization Treatment after Monitoring in the 6 Satellite Clinics. 
'" 
Satellite clinic Clinic 1 Clinic 2 Clinic 3 Clinic 4 Clinic 5 Clinic 6 
Oocyte retrievals 85 119 175 108 59 24 
Oocytes per retrieval (mean ± SD) 9.9 ± 7.3 8.8 ± 5.3 9.2 ± 6.2 lOA ± 7.9 8.6 ± 6.2 804 ± 5.8 
Fertilization rate (%) 43* 55* 47 50 48 51 
Embryos per retrieval (mean ± SD) 4.3 ± 4.9 4.8 ±4.0 4.3 ± 404 5.2 ± 504 4.1 ± 4.9 4.3 ± 4.2 
Embryo transfers (% §) 58 (68) 100 (84) 133 (76) 86 (80) 46 (78) 18 (75) 
Embryos replaced (mean ± SD) 2.5 ± 1.0 2.6 ± 0.9 204 ± 1.0 2.7 ± 0.8 2.6 ± 0.9 2.7 ± 0.8 
Cryopreservations II (% §) 20 (24) 34 (29) 42 (24) 41 (38) 12 (20) 10 (42) 
Clinical pregnancies (% m 18 (31) 31 (31) 38 (29) 19 (22) 13 (28) 7 (39) 
Multiple pregnancies (% **) 8 (44) 13 (42) 5 (13) 10 (52) 3 (23) 
Twins (% **) 5 (28) 12 (39) 5 (13) 8 (42) 3 (23) 
Triplets (% **) 3 (17) 1 (3) 2 (10) 
Embryo implantation rate (%) 20.5:f 17.2 1304 1304 13.6 14.3 
Viable pregnancies (% m 18 (31) 27 (27) 29 (22) 18 (21) 10 (22) 7 (39) 
Percentage male sub fertility 38' 13-i- 25 18 25 25 
*'1'1: Significantly different from other clinics II Data on thawings and cryopregnancies are 
(P < 0.01, P < 0.02 and P < 0.05 respectively). not included in this table. 
§ Percentage per oocyte retrieval. ** Percentage per clinical pregnancy. 
, Percentage per embryo transfer. 
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Chapter 2 
Minimal monitoring of ovarian hyperstimulation: a useful 
simplification of the clinical phase of in vitro fertilization 
Fertility and Sterility 1995;64:552-6. 
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SUllllllal'Y 
To investigate the feasibility of IYF treatment with minimal monitoring during ovarian hyper-
stimulation, a retrospective analysis and a prospective Shldy with a real-time control group was 
carried out. In a transport IVF programme with satellite clinics 100 consecutive IVF cycles 
monitored at the transport clinic (TC), and 100 concurrent consecutive cycles monitored at satel-
lite clinics (SC) \vere compared retrospectively for the number of ultrasound measuremcnts 
(USM) carried out during monitoring, and for results ofTVF treatment. Both TC and SC used the 
same stimulation/monitoring protocol. No patient sclection took place. All cycles resulted in oo-
cyte retrieval. After introduction of a minimal monitoring protocol at TC, a prospectivc study was 
stm1ed comparing 100 minimal monitoring cycles at TC ''lith 100 eonCUlTent conventional 
monitoring cycles at SC, all resulting in oocytc aspiration. Patients entered the retrospective or 
prospective Shldy only once. In aU cases the same laboratory facility was used. Monitoring of 
ovarian hyperstimulation was done with US:M only. 
Retrospective analysis showcd no difference for the average number of US~ll at TC and SC; 
2.8 ± 0.9 and 3.0 ± 1.0. No differences were fOllnd in the number of ongoing pregnancies ob-
tained in the two groups; 22 and 18 respectively. One case of severe OHSS occurred in the SC 
group. Introduction of minimal monitoring at TC gave a significant reduction of the average 
number of USM at TC comparcd to SC where conventional monitoring continued to be used; 1.5 
± 0.8 vs. 2.8 ± 0.9. Ongoing pregnancies at TC and SC numbered 33 and 26 respectively. In both 
groups one patient developed severe OHSS. Sixty-two percent of cycles at TC were monitored 
with one USM only. No cancellations for impending OHSS occurred during the study period. 
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Conclusion: A large group of patients need only one US:M during monitoring of ovarian by-
perstimuiation. Minimal monitoring gives a useful further simplification of the clinical phase of 
IVF treatment without adverse effects on treatment outcome and incidence of OHSS. 
Introduction 
In general ovarian hyperstimulation for in vitro fertilization (I\lF) is carefully monitored in order 
to determine the appropriate moment of oocyte retrieval, and to screen for signs of impending 
overstilllulation, possibly resulting in the development of the ovarian hyperstimuiation syndrome 
(OHSS). In most IYF programmes monitoring is cal1"ied out by repeated ultrasound scans and 
plasma estradiol (E2) measurements. Close monitoring is time-consuming, expensive and incon-
venient for the patient. The necessity of close monitoring has been debated (1, 2, 3). 
Suceesful I YF cycles have appeared to be equally distributed over the entire range of plasma 
E2 levels measured during ovarian stimulation. Therefore, the importance of E2 measurements for 
daily treatment policy with respect to timing of human chorionic gonadotrophin (HCG) admini-
stration should be reconsidered (4). Some IVF programmes have abandoned the use of hormone 
assays completely (3, 5, 6). Further simplification of IVF treatment by reducing ovarian stimula-
tion monitoring to a minimum, will cause less stress and inconvenience to thc patient. In order to 
further minimize the monitoring procedure, a minimal monitoring protocol was evaluated in a 
prospective study. 
Materials and methods 
In a transport IVF programme with satellite clinics the transport clinic (Zuiderziekenhuis) col-
laborates with the IVF laboratory at the University Hospital of Rotterdam. The complete clinical 
phase of IVF treatment: patient selection, determination of stimulation schedule, monitoring of 
ovarian stimulation, ovum pickup and follow-up after embtyo transfer, takes place at the transport 
clinic (TC). In the IVF laboratOlY at a separate location the laboratory phase including emblYo 
transfer is calTied out. Satellite clinics (SC) cany out stimulation and monitoring of ovarian hy-
perstimulation according to an identical protocol. All patients are treated with gonadotrophin-
releasing hormone agonists (GnRB-a); in most cases the flare-up schedule is used. Ovarian 
stimulation consists of human menopausal gonadotrophin (lllvlG, Humegon f.; Organon, Oss, The 
Netherlands) 150-450 ill/day, depending on age and indication for IYF, starting on cycle day 3 
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until the day of HCG injection. Monitoring of controlled ovarian hyperstill1ulation (COH) is done 
with transvaginal ultrasound measurements (US:M) only. At the transport clinic eight members of 
staff arc involved in monitoring; at the satellite clinics one to three. \Vhcn morc than 35 develop-
ing follicles are seen during monitoring, the cycle is cancelled by withholding ReG and continu-
ing GllRH-a in order to reduce the chance of development of OHSS. Human chorionic gonado-
trophin 10,000 IU (PregnyF; Organon) is given when> 50% of the leading follicles have reached 
an average diameter of 18-20 111m, followed by ovum pickup 35 hours later. Satellite clinics con-
tact the transport clinic when follicle size allows planning of HCG injection and ovum pickup. 
Oocyte retrieval is done under local anaesthesia, transvaginally and ultrasound guided. After the 
ovum pickup the patient's partner carries the aspirates in an insulated box containing a preheated 
(350 C) aluminium block to the central IVF laboratOlY at the University Hospital, distance 7 km, 
travelling time 15AO minutes. 
Oocyte isolation from the aspirates and subsequent laboratory procedures including emblYo 
transfer take place at the IVF laboratOlY. The laboratOlY procedure has been described by Huis-
man et a!. (7). Luteal suppOli is given with 1,500 IU HeG on the day of ovum pickup (day 0) and 
on days 3, 6 and 9. "'hen 15 or more follicles are found during ovum pickup, progesterone 200 
mg (ProgestanF-; Organon) vaginally, nvice daily, is prescribed for 15 days. In these cases HCG is 
withheld. A clinical pregnancy is defincd by a positive urinary test 18 days after oocyte retrieval 
combined with the finding of a gestational sac during ultrasound scanning nvo weeks later. A 
pregnancy is defined as ongoing when fetal hemt motion is observed after 12 weeks of amenor-
rhoea. 
\"ith the conventional monitoring schedule, the first ultrasound measurement was carried out 
after 5 days of stimulation with HMG. Timing of subsequent USM depended on findings during 
first US!v!. .Mollitoring continued until the leading follicles reach an average diameter of 18-20 
111111 and HCG is given. 
In order to compare the control data obtained in the nvo clinical settings, 100 consecutive IVF 
cycles, resulting in ovum pickup, monitored at the transport clinic and 100 consecutive cycles, 
resulting in ovum pickup, monitored at SC were compared with regard to the number of US:M 
during COI-I and the outcome of IVF treatment. This control study \vas included to investigate 
whether the monitoring policies at TC and SC were similar, and \vhether results of IVF treatment 
differed. If not, the patient group monitored at SC could serve as a control group in a prospective 
study. 
In the prospective study the monitoring schedule at TC ,vas minimized. The first USNI \vas 
carried out after 7 days of HlvIG, and, anticipating follicular growth of 1_-2 111m/day, !-lCG injec-
tion and ovum pickup were planned at that velY moment, provided> 25% of the follicles had 
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reached an average diameter 2:: 14 mm. If these criteria ,vere met, stimulation was continued, 
,yhen necessmy, for up to 4 days without any additonal USlY! and oocyte retrieval was planned. 
\Vhen findings during first USlv! did not meet the above mentioned criteria, a follow-up USlv1 was 
performed. The concurrent patient group at the SC continued to be monitored according to the 
conventional protocol. 
Patients entered the retrospective or prospective study only once. The OHSS classification of 
Golan et a1.(8) was used in this study. Statistical analysis was done with X~ test or Student's t-test 
,yhen appropriate. 
Results 
Retrospectively 100 consecutive IVF cycles monitored at TC ,yere compared with 100 concurrent 
consecutive cycles monitored at SC. No patient selection took place. In both groups the same 
monitoring protocol was used. During the period in which these cycles were monitored no can-
cellation of IVF cycles for impending development of OHSS occllITed. No statistically significant 
difference in age of the patients ofTC and SC was found: 31.9 ± 4.6 and 32.6 ± 4.8 years (mean ± 
SD). The results are shown in table 1. No differences ,vere found between the two groups for the 
mean duration of COH with IllvIG and the number of ultrasound measurements calTied out during 
stimulation. The clinical pregnancy rates: 29% (confidence interval [C.I.] 20-39) versus 21 % (C.1. 
13-30), and the ongoing pregnancy rates: 22% (C.r. 14-31) and 18% (C.1. 11-27) did not differ. 
For the frequency of multiple pregnancies a statistically significant difference ,vas found that can 
not be explained. One case of OHSS grade 4 occuned in the SC group. 
The results of the prospective study with minimal monitoring of 100 consecutive IVF cycles at 
the TC and conventional monitoring of 100 concurrent consecutive cycles at the SC are shown in 
table 2. During the study period no cancellations for impending OHSS occurred. No patient se-
lection took place. No difference was found for the mean age in the two groups: 32.2 ± 4.8, and 
32.9 ± 4.3 years. The results of the prospective study are shown in table 2. 1vlinimal monitoring 
during COlI resulted in a significant reduction in the number of ultrasound measurements carried 
out. The results in table 2 indicate that the minimal monitoring protocol had no adverse effects on 
the outcome of IVF treatment. The duration of COH and the oocyte yield in the two groups did 
not differ. The differences in clinical pregnancy rates: 38% (C.r. 28-48) versus 28% (C.1. 19-38), 
and ongoing pregnancy rates: 33% (C.r. 24-43) versus 26% (C.r. 18-36), were not significant. In 
both groups one case of OHSS grade 4 occuned. The pregnancy rates in the prospectively studied 
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group were higher when compared to the retrospectively reviewed populations. However, the dif-
ference was not statistically significant (P> 0.05). 
Table 1. Treatment Results of Retrospective Analysis ,,,ith Conventional Ivlonitoring at Transport 
and Satellite Clinics. 
Ovum pickups 
Flare-up schedule GuRH-a 
Days hMG * 
Number of USM * 
Oocytes at pickup * 
Embryos * 
Cryopreservations t 
Emhlyo transfers 
Embryos replaced *+ 
Clinical pregnancies 
Multiple pregnancies §II 
Ongoing pregnancies 
Emhlyo implantation rate 
Severe OHSS '1 
* Values are means ± SD. 
COllventionalmonitoring 
Transport Clinic 
100 
85 
9.2 ± 2.2 
2.8 ± 0.9 
9.4 ± 6.8 
4.9 ± 5.1 
38 
76 
2.4 ± 0.5 
29 
3 (14) 
22 
17.7 % 
o 
t Data on thawings and cryopregnancies are not included in this table. 
+ Per cmblYo transfer. 
§Values in parentheses are percentages per clinical pregnancy. 
Conventional monitoring 
Satellite Clinics 
100 
88 
9.1 ± 2.4 
3.0 ± 1.0 
9.2 ± 6.9 
5.5 ± 5.3 
40 
82 
2.5 ± 0.5 
21 
10 (55) 
18 
16.2 % 
II Significant difference TC versus SC, P < 0.05. Other comparisons not significantly different. 
~ Classification Golan (8) 
The number of ultrasound measurements during COH and the duration ofHNIG stinmlation in 
the prospective study is shown in figures I and 2. At Te, where the minimal monitoring protocol 
was used, 62% of oocyte retrievals could be plmmed after one ultrasound measurement only. The 
remaining patients needed a more individual approach. The new monitoring protocol resulted in 
an almost 50% reduction of patient visits to the hospital during the stinmlation phase. 
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Table 2. Treatment Results of Prospectivc Study with Minimal fvIonitoring at Transport Clinic 
and Conventional I'VIonitoring at Satellite Clinics. 
Ovum pickups 
Flare-up schedule GnRH-a 
DaysHMG * 
Number of USM *t 
Oocytes at pickup * 
EmblYos * 
Cryopreservations t 
Embryo transfers 
EmblYos replaced *§ 
Clinical pregnancies 
Multiple pregnancies II 
Ongoing pregnancies 
Embl)'o implantation rate 
Severe OHSS '1 
* Values arc means ± SD. 
fvlillimaimonitoring 
Transport Clinic 
100 
93 
9.6 ± 2.5 
1.5 ± 0.8 
9.2 ± 6.8 
5.0 ± 4.2 
36 
92 
2.2 ± 0.7 
38 
6 (16) 
33 
22.1 % 
Conventional monitoring 
Satellite Clinics 
100 
96 
9.4 ± 2.5 
2.8 ± 0.9 
8.7 ± 6.3 
5.1 ±4.9 
34 
87 
2.3 ± 0.7 
28 
8 (29) 
26 
18.2 % 
t Significant difference, transport versus satellite clinics, P < 0.0001. All other comparisons not 
significantly different. 
t Data on thawings and c1),opresel'vations arc not included in this table. 
§ Per embl)'o transfer. 
II Values in parentheses are percentages per clinical pregnancy. 
11 Classification Golan (8) 
Discussion 
A major clinical development in IVF treatment during the past ycars has bcen the simplification 
of the treatment procedure (2). The laparoscopie oocyte retrieval has been replaced by the ultra-
sound guided transvaginal oocyte aspiration. Precise timing of RCG injection and ovum pickup 
35 hours later have proven to be unnecessalY after pituitary desensitization with GnRH-a (2, 9). 
The intensity of the monitoring of IVF cycles has already been reduced in several programmes 
(3). Monitoring during COH for IVF is carried out in order to determine the appropriate moment 
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of HCO injection and oocyte retrieval, and to screen for signs of impending development of 
OHSS. Repeated ultrasound scans and honnone assays are inconvenient, expensive and tinle-
consuming. The necessity of intensive monitoring during ovarian hyperstimulation has been de-
bated. Programmed IVF, using clomiphene with ITh10 on altemate days for stimulation, with 
limited monitoring only, has been recommended before (I, 5, 10). 
Figure 1. The number of USM and duration of HNIG stimulation with minimal monitoring at the 
TranspOJi Clinic. 
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\Vith the use of the OnRH-a, urine tests to screen for early luteinizing honl1one peaks are not 
necessary anymore. High or low E2 levels \'lere found not to bc detrimental to the clinical out-
come ofIVF treatment (4, II). IVF pregnancies occur in the presence ofa wide range ofE2 levels 
during the three day period preceding follicle aspiration, indicating that E2 measurements arc not 
necessary for succesful pregnancy induction (4). For these reasons the use ofhor111one assays has 
been abandoned completely in some programmcs (3, 5, 6, 12). In these programmes ultrasonic 
scanning of follicular size is used as the sale index of follicular mahlrity. An average number of 
three ultrasound scans dnring each treatment cycle has been reported (3). 
In our transpOli IVF programme, monitoring of COH has always been limited to ultrasound 
scans only. In order to reduce the monitoring procedure further, a minimal monitoring protocol 
was introduced. The first ultrasound scan was calTied out after 7 days of HMO administration. 
\Vhen the criteria described were met, normal further development of follicles was anticipated and 
37 
oocyte retrieval was planned. After introduction of this monitoring protocol the number of ultra-
sound scans and patient visits during the stimulation phase was reduced by almost 50%. Sixty-two 
percent of IVF cycles \vere monitored with one ultrasound measurement only. No adverse effects 
on the outcome of IVF treatment were found. Although the pregnancy rates in the group \vith 
minimal monitoring were higher compared to the group with conventionaimonitoring, the differ-
ence was not statistically significant. Finding a difference for pregnancy rate between the two 
groups was not an objective of this Shldy and would have called for a far larger sample size. In 
addition, a better outcome of IVF treatment is not to be expected from less intensive monitoring. 
Pregnancy rates in the prospectively studied groups were higher compared to the retrospectively 
studied groups, although the difference was not statistically significant. In an earlier study evalu-
ating the results of 2207 consecutive IVF cycles in the same programme, a pregnancy rate of 
28.7% was found for both transport clinic and satellite clinics (13). It appears that the results of 
the shldies described illustrate the occasionally occurring fluctuations of results in an IVF pro-
gramme. 
Figure 2. The number ofUS1vl and duration oflllvlG stimulation with conventional monitoring at 
Satellite Clinics. 
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In IVF treatment the development of mild ovarian hyperstimulatioll, allowing recruitment of a 
cohort of mahHe foHicles, is a primalY goal. The development of an OHSS hmvever, can not be 
prevented in all IVF cycles. Estradiol peak level and rate of increase, dose of HMO, size and 
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number of follicles developing and the number of oocytes collected are parameters used for the 
prediction of thc development of OHSS. A considerable overlap of distributions of these values 
between control and OHSS populations has been found (14). In order to increase predictability of 
OHSS, a fonnula for prc-oocyte retrieval conditions was established in a multiple discriminant 
analysis, yielding a prediction rate for the development of moderate or severe OHSS of 76.1 % 
with a false ncgative rate of 18.1% (15). This fonnula can only be used after frequent hormonc 
assays have been carried out and calls for an intensive and expensive monitoring procedure. How-
ever, OHSS is 110t prevented in all cases. The value of ultrasonography in predicting the develop-
ment of OHSS by llumber and size of follicles has been assessed (16). In view of this, cycles in 
the present Shldy were only cancelled for impending development of OHSS when more than 35 
follicles, with a diameter;::: 10 111111, were seen to develop during COl-I. No cancellations for this 
reason occurred during the study period. Nevertheless, three cases of severe OHSS were found in 
our study groups, one in the group with minimal monitoring, two in the groups with cOllventional 
monitoring. This incidellce ofOHSS (0.75%) is comparable with the results of programmes using 
combincd ultrasound measurcments and honnone assays (17). 
In conclusion: minimal monitoring simplifies IVF treatment, causes less inconvenience for the 
patient and is more cost-effective. The outcome of IVF treatment is not affected and the inci-
dence of development of OHSS does not appear to be increased. 
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Summary 
For routine use of gonadotrophin-releasing hormone agonists (GnRH-a) in an IVF programme the 
short flare-up protocol and the long protocol give comparable clinical results. Both protocols are 
useful for organizational purposes and offer important logistical advantages for IVF programmes. 
In tenns of cost, time and inconvenience for patients the short flare-up protocol seems to be the 
most appropriate regimen for routine lise. The intranasal administration of GnRH-a appears to be 
equally efficacious when compared with the subcutaneous route. 
Introduction 
Gonadotrophin-releasing hormone agonists combined with human menopausal gonadotrophin 
(H1\1G) are now widely used for controlled ovarian hyperstimulation (COH) in IVF programmes. 
Initially GnRH-a were introduced as a pretreatment before COH after tailed IVF attempts (1-5). 
The administration of GnRH-a gives an initial stimulatOlY phase ("flare-up") followed by down-
regulation of pituitary GnRH receptors, resulting in the reduction of the release of gonadotrophins 
by the pihlitary gland. This suppressive effect of agonists on the endogenous gonadotrophins 
leads to ovarian quiescence, and prevents the recruitment of follicles induced by pituitmy FSH, 
that is optimally initiated in the late luteal phase of the preceding cycle. The administration of 
gonadotrophins when pihtitary suppression and ovarian inactivity arc achieved, results in a syn-
chronous development of a larger cohort of follicles, and consequently in a larger oocyte yield 
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and lower cancellation rate (6). With the administration of GnRH-a during COH, the developing 
Docytes are protected from perturberations in luteinizing h0l1110nC (LH) release which are thought 
to be detrimental to the normaimaturatioll of the egg (7, 8). Also, beneficial effects in patients 
with high tonic UI levels have been described (9). Smitz et al. (3) reported occurrence of a pre-
mature surge ofLH without the use ofagonists in 15% to 30% of patients. Loumaye (10) found 
that without the use of GnRH-a one half of oocyte collections were timed by an endogenous LH 
surge, whercns the other half were timed by HCG administration. Through the control of the 
preovulatOlY LH surge spontaneous ovulations arc prevented and expensive and cumbersome 
monitoring in order to detect a putative LH surge is not necessary. Therefore, the timing of oocyte 
retrieval has become less critical (11), giving considerable organizational advantages for IVF pro-
grammes, and making programmed NF possible (12, 13). 
Different protocols have been developed for the use of GnRH-a in IVF: the long down-
regulating protocol, and the short 'flarc-up' and ultra-short protocol. Some aspects of thcse proto-
cols will be discllssed with an cmphasis on the logistical advantages of thc use of agonists during 
COHo Furthermore, the experiences with GnRH-a in the transport IVF programme at the 
Zuiderziekenhuis, Rotterdam, are reported. 
The long down-regulating protocol 
The logistic advantages of the use of the long down-regulating protocol in IVF have been stressed 
by several authors (14-16). Wikland et al. (15) described a considerable simplification of the 
monitoring of COH, and avoidance of oocytc collections during weekends, without a decrease in 
pregnancy rate. In the long dmvn-regulating protocol the administration of gonadotrophins for 
ovarian hyperstimulation is started after pituitary down-regulation is achieved. 
Conflicting reports have been published with respect to the prefened phase in the mcnstl11al 
cycle for starting desensitization. Good results with the initiation of GnRH-a in the early follicular 
phase have been reported by Pellicer et al. (17). Urbancsek and Witthaus (18) conducted a mul-
ticenter study and found that clinical and live birth rates arc higher when the agonist was started 
in the midluteal phase rather than in the early follicular phase. Two recent studies found compara-
ble IVF results after starting down-regulation in different phases in the menstrual cycle: Ferraretti 
et al. (19) found that agonists can be started irrespective of the cycle phase, and Konaveeti et al. 
(16) reported that both follicular and luteal phase initiation of GnRH-a are equally efficacious. 
Although long-acting GnRB-a is more convenient for patients than a daily administration of a 
short-acting one, it has been rep0l1ed that long-acting OnRH-a might interfere with the luteal 
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phase and embryo development (20, 21). Therefore, short-acting GnRH-a should be preferred for 
COR. 
A disadvantage of starting the administration of agonists in the luteal phase is the possible 
presence of a pregnancy. There arc indications that GnRH-a may have a detrimental effect on 
corpus lutcum function by a direct effect on the ovary (22), In experimental studies an increase ill 
major fetal abnonnalities has been found after administration of a depot suspension of GnRH-a 011 
day 6 of pregnancy in rabbits (23). Although several authors reported nonnal pregnancies despite 
the use of GnRI-I-a in thc fIrst trimester of pregnancy (24-28), the potential for teratogenicity may 
exist and caution is indicated. 
With thc use of GnRH-a in the long protocol thc costs of medication in IVF have increased. 
The treatment cycle is lengthened by the time needed to achieve down-regulation. Complete 
down-regulation can be assessed by serum estradiol (E2) estimations and ultrasound examinations 
of the ovaries to screen for follicular activity. Therefore, although the long protocol has practical 
advantages for the organization of IVF programmes, the disadvantages for patients in terms of 
cost, time, and inconvenience can not be ignored. 
The short flare-lIjl jlrotocol 
The short flare-up protocol makes use of the initial release of endogenous gonadotrophins to 
augment follicu lar recmitment and the suppression of endogenous gonadotrophin secretion there-
after. In this protocol the agonist is started in the early follicular phase of the cycle, followed by 
the administration of gonadotrophins 1-3 days later. \Vhen the agonist is continued until the day 
of BCG administration, the protocol is called the short protocol, and, if it is administered for an 
initial 3 days only the ultra-shori protocol. Initially meant to block the LH surge during COli (29), 
it appeared that the "flare-up" effect, i.e., the initial gonadotropWc stimulation induced by the 
analogue prior to gonadotrophic descnsitization, could playa role in thc shorter duration of ovar-
ian stimulation (30, 31). It has been reported that the flare-up protocol might be the therapy of 
choice for patients at risk of a poor ovarian response during COIl (32, 33). 
The short-tclTIl GnRH-a regimen can be combined with progestagen pretreatment to allow for 
an advanced scheduling of the moment of oocyte retrieval (34). It has bcen shown that the ovarian 
response to COli with the flare-up protocol is not affected by progestagen administration in the 
previous cycle, ilTespective of the patient's age (35, 36). Although pretreatment with norethis-
tcrone decreases the E2 flare-up, the predictive value of the initial change in E2 level reported by 
Winslow et al. (37) is not changed, and the outcome of the IVF cycle is not influenced (38). 
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Between Januaty 1989 and August 1996, 1825 patients had their first IVF cycle in the trans-
port IYF programme at the Zuiderziekcnhuis in Rotterdam. The flare-up protocol was used in 
1598 cases (88%), the long protocol with a midluteal start of GnRH-a in 89 cases (5%). The re-
maining 138 patients (7%) were treated without GnRH-a during COH in their first IVF cycle. 
Monitoring of COH was calTicd out without El determinations and with transvaginal ultrasound 
measurements only. Despite the limited monitoring procedure (39), a spontaneous ovulation oc-
curred in only 5 cases (0.3%) in thc group treated with the flare-up protocol. This compared fa-
vourably with the 4 cases (3%) of spontaneous ovulation in the patient group treated without ago-
nists (P < 0.0 I, x' test). Spontaneous ovulation did not occur in the group of 89 patients treated 
with the long protocol. In the flare-up protocol four different GnRH agonists were used, thrce for 
subcutaneous injection: leuprolide (Lucrin', Abbott), buserelin (Suprefact", Hoechst), and trip-
torelin (Decapeptyl'-, Ferring), and one for intranasal use: nafarelin (SynareF, Searle). 
Table 1. Results of First IVF Cycles with the Flare-up Protocol. 
Leuprolide Buserelin 
1 mg s.c, 500 fIg s.c. 
Statied cycles 720 114 
Cancelled, poor response * 20 (2.8) 4 (3.5) 
Cancelled, other reasons 2 0 
Premature ovulation 
Oocyte retrievals 697 109 
Ooeytes retrieved t 10.0 ± 6.8 12.3 ± 10.3 
Clinical pregnancies t 168 (24) 21 (19) 
Ongoing pregnancics t 144 (21) 18 (17) 
* Values in parentheses are percentages of started cycles. 
t Values in parentheses are percentages per oocyte retrieval. 
t Means± SD. 
Triptorelin 
0.1 mg s.c. 
387 
7 (1.8) 
2 
377 
1l.l±7.6 
82 (22) 
63 (17) 
Nafarelin intranasal 
200 fIg b.d. 
377 
8 (2.1) 
2 
366 
lOA ± 7.0 
92 (25) 
76 (21) 
The results of these cycles are shown in table l. Obviollsly, the clinical results of the fOllr agonists 
in the shOli protocol are comparable. In table 2 the results of the two different routes of admini-
stration of GnRH-a, intranasal1y fOf nafarelin and subcutaneously for buserelill, leuprolide and 
triptorelin, are compared. No statistically significant differences were found for the different pa-
rameters (i~ tcst and Student's t-test used where appropriate). In this retrospective analysis of aUf 
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population, the intranasal administration of GnRH-a appeared to be equally efficacious when 
compared with the subcutaneous administration. 
The easy intranasal administration of na£1relin and the good clinical results described in sev-
eral studies (40, 41) have made nafarelin an option for use in COH for IVF. The efficacy of in-
tranasal nafarelin in the flare-up protocol has been described (42). The results obtained with na-
farclin in the short protocol in the transport IVF programme confirm these findings. 
Table 2. Results of the Flare-up Protocol with Intranasal versus Subcutaneous GnRH -8 in First 
IVF Cycles. 
GnRH-a s.c. GnRH-a intranasal 
Started cycles 1221 
Cancelled poor response * 31 (2.5) 
Premature ovulation * 4 (0.3) 
Oocyte retrievals 1183 
Oocytcs retrieved j: 10.6 ± 7.5 
Clinical pregnancics § 271 (23) 
Ongoing pregnancies § 225 (19) 
* Values in parentheses are percentages of stat1ed cycles. 
f NS, not significant, X' test. 
t Mcans ± SD. 
§ Values in parentheses are percentages per oocyte retrieval. 
Long protocol verSLIS short protocol 
375 
8 (2.1) 
1 (0.3) 
366 
lOA ± 7.0 
92 (25) 
76 (21) 
P value 
NSf 
NS 
NS 
NS 
NS 
Although several studies have shown that thc combination of GnRH-a with HMG rcsults in higher 
pregnancy and live bil1h rates and reduced cancellations due to poor follicular response or pre-
mature luteinizing hormone surges (6, 43, 44), the routine usc of GnRH-a for patients undergoing 
IVF appears to have more practical than medical advantages (45, 46,19). However, the combina-
tion of GnRH-a and gonadotropins has become the most widely used regimen for COH in IVF 
programmes. The different protocols used for GnRH-a have been compared in several studies. In 
thc first randomized study comparing long and shOit protocols Flydman et aJ. (47) concluded that 
the clinical results of the two protocols are similar, and that other factors should be taken into ac-
count when deciding what protocol is to be used. Conflicting results have been published by other 
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authors. In a meta-analysis often prospective randomized clinical trials, Hughes et al. (44) found 
no significant differences between the long and short protocol with respect to cycle cancellation 
and pregnancy rates. Tan et a1. (48) reported higher probabilities of conception and live birth with 
the long protocol, but this study ,vas retrospective. 
In the short protocol the initial release of endogenous gonadotrophins augments follicular re-
cruitment. A shorter duration of stimulation and lower doses of exogenous gonadotrophins needed 
using the short protocol have been reported in comparative studies (34, 49). However, in several 
other studies no effect of the "flare-up" effect itself could be demonstrated when the stimulation 
requirements in the short and the long protocol were compared (47, 49-51). In patients at risk of a 
poor response the short flare-up regimen seems to have advantages over the long protocol (32, 
33). Muasher (32) stated that prior suppression with GnRH-a in poor responders might result in 
excessive dampening of the ovarian response. The suppression of LH levels throughout the late 
follicular phase may not be as complete with the short protocol as with the long protocol. Ele-
vated endogenolls LH levels have been reported to lead to a higher incidence of poor fel1ilization, 
failure of implantation and early abortion (7, 8). Acharya et al (50) found no premature LH surge 
with the flare-up protocol in any of the cycles studied. However, LH surges might occur more 
f}-equently with the ultra-short protocol (52). 
The logistical advantages of the long and the sh0l1 protocol are comparable as programmed 
IYF has been described using both regimens. The feasibility of minimal monitoring during COH 
with both protocols has also been reported (15, 39) 
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Introduction 
Delayed childbearing is increasingly common in the westcm world. The availability of measures 
for birth control, educational and career priorities for women, and the increased rates of divorce 
and rcmalTiage arc factors causing this phenomenon. Postponement of childbearing simultane-
ously increases the chance of exposure to sexually transmitted diseases and correlated infertility 
due to tubal dysfunction. Possible sub- or infertility will bccome evident at a higher age. The de-
crease in fecundity (ability to procreate) ofvlOmen of advanced age is generally known. Schwartz 
and I\1ayaux (1) analysed the results of artificial insemination in 2193 nulliparous women with 
azoospermic husbands and found evidence for a decrease in fecundity of women after the age of 
30. Postponement of childbearing resulting in prolonged exposure to factors affecting fecundity, 
combined with the natural reduction of fecundity, causes an increased proportion of patients in 
the higher age groups to consult infertility services. The patient's age should be taken into account 
when treatment choices are made to correct infertility. 
Treatment of infertile patients, after documenting tubal patency, with ovarian stimulation and 
intra-uterine insemination has shown a very low success rate in \"omen above 40 years of age. 
Fredcrick et al. (2) rcported a 5% prcgnancy rate per cycle in patients abovc 40 years compared to 
10% in the group below 40 years. In these patients the most efficacious treatment for infertility 
should be chosen since they have only few reproductive years left. Consequently, assisted repro-
ductive tcchnologies (ART) are frequently applied in higher age groups. However, thc limited 
results obtained in patients above the age of 40 years make the utilization of techniques for as-
sisted reproduction controversial in these cases. Advanced age is correlated with a poor response 
to controllcd oVal;an hypel~till1ulation (COB) for IVF (3) and high cancellation rates during COB 
(4, 5). The pregnancy rates of patients above 40 years arc decreased and the rates of miscarriage 
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are highly increased when compared to lower age groups. Padilla and Garcia (6) found a 9% on-
going preg1lancy rate per emblYo transfer (ET) in patients aged 37 years compared with a 26% 
ongoing pregnancy rate in patients younger than 30 years. Results from The American Fertility 
Society Registry (5) show a 10.8% delivery rate per ET in patients above 39 years compared to 
30.4% below 40 years. Tan et a1. (7) found a cumulative conception and livebirth rate after five 
treatment cycles of about 54% and 45% respectively at 20-34 years, compared with 20.2% and 
14.4% above 40 years. Results of 492 TVF units, collected from national surveys and registries of 
different countries, over the period 1985-1989 show a live birth rate of 5.8% per transfer cycle 
above the age of 40 years (8). Check et al. (9) found a significant effect of age in patients above 
35 years with multiple factors causing infertility in a prospective study. 
The miscaniage rate in IVF pregnancies above 40 years varies between 41-62.5% of clinical 
pregnancies (5, 6, 8, 10). Poor results obtained in the patient group aged 40 years or more has led 
to an age limit for acceptance for IVF treatment in most government supported programmes. 
However, one can ask the question whether a strict age limit for acceptance of patients is justified 
since the patient's perfol1nance in ART appears to be more closely related to ovarian age than to 
chronological age (3). Other clinical parameters like prevalence of spontaneous menstrual cycles 
or even normal ovulatory cycles, can not be used for an adequate prediction of the response to 
COH (11). Endocrine parameters proved to be more useful as a prestimulation test and can be 
used for counselling patients on their chances for a succesful ovarian stimulation for IVF treat-
ment. The determination of basal follicle-stimulating honnone (FSR) levels (3), clomiphene eit-
rate stimulated FSH levels (12), and 
stimulation test (13) prior to 
the gonadotrophin-releasing hormone agonist (GnRH-a) 
COR have been proposed in this respect. 
Several stimulation protocols have been developed in order to improve the outcome of IVF 
treatment in patients with a poor prognosis or a previous poor ovarian response to COR (14-18). 
More effective stimulation protocols might improve the IVF results in patients of thc higher age 
groups. 
Assisted hatching has been proposed as a mcthod to improve the implantation rate in cases 
with a poor prognosis. Cohen (19) and Schoolcraft (20) advised this micro manipulative procedure 
for patients aged above 38 and 39 years respectively. 
According to several authors replacement of more than two emblYos should be avoided in 
IVI'-cases with a good prognosis (21, 22). The emblyo implantation rate has been reported to de-
cline after the age of 35 and appears to be low in patients above 40 years (23, 24). In rVI' pro-
grammes ,vith similar results, replacement of 3 or 4 embryos seems justified after the age of 40 
years, thereby enhancing chances for a favourable outcome. However, the prevalence of triplet 
pregnancies should remain a concern when decisions on embryo replacement policy are made. 
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Oocyte donation (OD), with oocytes obtained from a younger donor, appears to be a good al-
ternative for women in the higher age groups who have failed to achieve a pregnancy with their 
own oocytes due to a poor response to ovarian stimulation (25-27). As a result of OD pro-
grammes, pregnancies and deliveries in elderly and postmenopausal women have been reported. 
Age limitation in OD programmes is highly controversial. By only selecting women in good 
health as acceptors of oocytes it is reasonable to expect that the incidence of complications will be 
reduced (28). 
Methods to select patients in the higher age groups with a fair chance for a suceesful outcome 
of IVF treatment, and the various possibilities to enhance the chances for a suecesful pregnancy 
are discussed hereafter. 
Prestimulation tests 
Increased ovarian age, resulting ill decreased ovarian function and diminished ovarian reserve, 
can cause a poor follicular response to COH (3). \Vhen a "poor ovarian response" occurs, mean-
ing that only one or two follicles develop, the IVF cycle can be cancelled, or the procedure can be 
continued, consequently with a velY limited chance ofsllcces. It would be useful ifpatients ,,,itlt a 
poor response to ovarian stimulation could be identified before a time-consuming, stressful! and 
expensive IYF procedure has been started. 
lVluasher et al. (29) investigated the predictive value of basal gonadotrophins for the quality of 
COH in a prospective study. It was concluded that measurement of basal serum gonadotrophin 
levels offers the possibility to distinguish between populations of IVI' patients who tend to behave 
differently in estradiol (E2) response, numbers of oocytes obtained, embryos transferred and preg-
nancy rates. Follicle-stimulating hormone levels on cycle day 3 have also been shown to be prew 
dictive of IVF outcome by Scott et al. (30). The authors distinguished three patient groups with 
different basal FSH levels « 15 mIU/ml, 15-24.9 mlUlml and >25 mlUlml) showing signifi-
cantly different ongoing pregnancy rates (17.0%, 9.3% and 3.6%). Toner et al. (3) reported results 
of 1478 consecutive 1VF cycles, analyzed to determine if basal FSH levels and age are indcpend-
ent predictors of 1VF performance. Pregnancy rates declined as age and basal FSH increased. 
Pregnancy rates per attempt steadily declined as basal FSH increased up to 20 mIUlml, thereafter 
the decline ,vas abrupt. Less than 5% term pregnancies per IVF attempt were found in cases with 
a basal FSH > 25 mlU/ml. The relationship between increasing age and pregnancy rate per IVF 
attempt was steady throughout the observed age range. Ongoing pregnancy rates fell from 28% 
percent in patients in their midwt'lventies to 12 % around the age of 40 years. The risk of cancella-
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tion of the IVF attempt was strongly related to basal FSH level (FSH 2: 30 mIU/ml : 40% canccl-
lation rate). However, no relationship was found between cancellation rate and age. The authors 
conclude that the basal FSH level is a better predictor of IVF perfonnancc than age. The clo-
miphene citrate (CC) challenge test was used by Navot et a!. (31) to prospectivcly assess the fer-
tility potential in 51 women aged 35 or more with unexplained infertility. Although all women 
had a nonnal baseline FSH and regular menstmal periods, 18 had a high FSH response of 26 
mlU/ml or morc (> 2 standard deviations above control levels) after administration of 100 mg 
clomiphene from cycle day 5-9. In this group one out of 18 patients coneieved compared to 14 of 
the 33 patients with a normal FSH response. There was no difference in age between the groups 
(40.0 and 39.6 years respectively). 
Taubo ct al. (32) found poor responders to ovarian hyperstimulation with an abnormal FSH re-
sponse to CC to have a low chance of success in further IVF attempts. The total pregnancy rate 
per patient, including spontaneous conceptions during the study period was 4% in the abnormal 
response group, compared to 33% in the nonnal response group. In a later prospective study, 
Tanbo et a!. (12) showed the CC challenge test to have a better prospective value than the basal 
FSH level. In a group of 37 patients with an exccssive FSH response to CC administration, 46 
(85%) of 54 cycles were cancelled because of poor response to ovarian stimulation. Loumaye et 
al. (33) used the sum of basal FSH (FSHI) and FSH (FSH2) after CC intake as the parameter cor-
relating best with a subsequent response to COH. This way the dependency on putative FSH assay 
inaccuracy and fluctuation of the FSH concentrations due to pulsatile excretion was reduced. The 
reference value for FSHI + FSH2 was detemlined to be 26.03 mIU/ml. The number of follicles 
aspirated, oocytes retrieved and embryos obtained were on average six times lower in the 20 paw 
tients with a CC challenge test above this reference than in 20 controls ,vitlI a tcst result within the 
reference limits. J 11 the group with an abnonnal test result no pregnancy was obtained. 
Olivennes et a1. (16) described the exogenous FSH ovarian reserve tcst. \Vhen a poor ovarian 
response is expected i.e. age> 37 years, or when cycle irregularities, ovarian pathology or poor 
response in previous cycles have been found, patients recieve 300 IV of purified FSH on the third 
day of the menstrual cycle. Basal FSH and E, level before FSH administration, and the E, level 24 
hours later are detcrmined. With a basal FSH > 10 mlU/ml and an E, increase < 30 pg/ml the 
prognosis was considered poor. 
Padilla et a1. (34) investigated the prognostic value of the early serum El pattern in response to 
leuprolide acetate in a GnRHwa flarewup protocol. In patients ,,,itII an absent early E2 response bew 
fore ovarian stimulation started on cycle day 5, the clinical pregnancy rate per cycle was 6% 
compared to 37% in the group with rising cstradiol levels. 
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Winslow et a!. (13) also described a OnRH-a stimulation test used in a group of 228 patients 
\vith a mean age of 36.6 ± 3.6 years. In contrast to Padilla et al. these authors found no significant 
correlation bctwecn the early E, paltem and the pregnancy rate. In their study they concluded that 
the initial change in El level is a sensitive predictor of performance in the flare-up IVF cycle. Pa-
tients who had less than a doubling of their E, level on cycle day 3 compared to day 2 had a high 
cancellation rate (39%) during subsequent ovarian stimulation with gonadotrophins. 
Controlled ovarian hyperstimulation in "poor responders" 
Although the first successful IVF treatments were achieved in spontaneous cycles (35), COB is 
now used prior to Doeyt retrieval. \Vith COB, more Docytes can be obtained during follicle aspi-
ration and a higher number of embryos available for replacement consequently leads to higher 
pregnancy rates (23). A poor response to ovarian stimulation is more frequently seen in higher age 
groups and this often leads to cancellation of IVF cycles. The definition of poor response differs 
between authors (15, 18,24,36). An E, level < 300 pgimL and fewer than three follicles with 
diameter> 15 I1ml prior to administration of human chorionic gonadotrophin are the most fre-
quently mentioned criteria. Shldies with poor responders are characterized by a selection bias and 
results from different studies are frequently contradictive. Thus, proposing an optimal treatment 
for poor responders to COH is one of the challenges in assisted reproduction. Increase of thc 
doses of human menopausal gonadotrophin (HMG) docs not necessarily lead to a better follicular 
response. Interestingly, Ben-Rafael et a!. (37) found a higher number of oocytes obtained after 
stimulation with 150 IU HMO daily as compared to that with 225 IV. Benadiva et a!. (38) studied 
hormonal profiles and follicular growth in high and low responders \"ith different doses of HMG. 
In low responders they found no positive effect of higher doses HlVIG on E2 concentrations or on 
follicular development. However, the number of patients in this shldy was 10\v (8 high responders 
versus 6 100v responders) and the difference in mean agc between the groups was considerable (31 
± 1.5 and 35 ± 1.8) although not significant in this small group. In support of this study, Kmande 
et a!. (39) found no improvement in oocyte yield after high-dose FSH stimulation at the onset of 
the menstrual cycle in low-responding patients. In the same study no beneficial effect \vas found 
of the administration of 6 ampules of pure FSH instead of 4. However, other authors have found a 
positive effeet of the administration of higher doses of gonadotrophins in poor responders. Hoff-
manl1 et a1. (18) treated patients with one or more previous poor responses to COlI with high 
doses of FSH (450 JU instead of 300 IU daily). There was no difference in age (36.1 ± 3.3 and 
36.3 ± 2.9 years respectively) or basal FSH levels between the two patient groups. High dose cy-
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cles showed a significantly lowcr cancellation rate and a higher pregnancy rate. The numbers of 
oocytes retrieved and cmbryos transferred were also higher after administration of FSH 450 IV 
daily but these differences were not significant. 
Doubling the HMG (225 IU to 450 IU) dose in the course of an IVF treatment cycle in low re-
sponders appeared not to bc effective to enhance the ovarian response in a prospective, random-
ized study by Van Hooff et aJ. (40). 
Changlng a stimulation protocol using Hi\1G only, to a protocol combining clomiphene citrate 
and HIVfG, does not improvc the ovarian response in a group of poor responders as rep0l1ed by 
Pelliccr et al. (41). The authors obsCived no significant differcnce betwecn the two stimulation 
protocols with regard to the cancellation rate or the number of oocytes retrieved per cycle. 
The use of GnRH-a suppression followed by COH has generally proven to be useful in 1011'-
cring cancellation rates, improving follicular growth and the yield ofoocytes in IVF treatment(42, 
43). Serafini (14) reported a beneficial effect of the use of GnRH-a in a group of poor responders 
with normal basal FSH levels. By contrast, other authors (J 5, 44) advise to avoid GnRH-a sup-
pression prior to COH ill low responders when the disorder is located at the ovarian level and not 
at thc hypothalamic/pituitary level. The short flare-up GnRHa protocol secms however to have a 
place in the treatment of poor responders. Muasher (J 5) described a modified flare-up GnRHa 
protocol combincd with high-dosage FSH (450-600 IU) in a step-down manner for previous poor 
responders. They reportcd a cancellation rate of 5% and a 21.3% clinical prcgnancy rate per cycle. 
Adjuvant growth honnone (GH) treatment, after pituitary suppression, has been proposed for 
ovarian stimulation in order to improve the results. Owcn et al. (45) investigated the effect ofGH 
cotreatment in 25 IVF patients who had previously responded suboptimally to ovarian stimula-
tion. In their study the authors found that a significantly higher number of follicles developed 
during stimulation with GH eotreatment. However, tiom tIus study it can not be concluded that 
GH is beneficial to poor responders in general. A previous suboptimal result ,vaS defined as less 
than 6 oocytes obtained during a previous IVF cycle. Besides, the augmentation of ovarian re-
sponse the authors found, was only seen in the large subgroup ,vith polycystic ovarian syndrome. 
Hughes et aJ. (46) and Bergh et al. (47) could not fInd a beneficial effect of the use of GH in ran-
domized, double-blind, placebo-controlled studies. Therefore, it can be concluded that the use of 
GH in patients with a previous poor response to COH due to increased ovarian age is not indi-
cated. 
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Use of assisted hatching 
Impairment of healthy embryos to hatch from the zona pellucida has been postulated by Cohen et 
a1. (48) as one of the causes for early embryonic demise in IVF procedures. A micromanipulation 
to promote hatching by introducing an artificial incision ill the zona pcllucida of early cleaved 
emblYos prior to replacement was described. According to the authors this procedure facilitates 
the hatching process mechanically and so they called it assisted hatching. One should bear ill 
mind however, that the occunellCC of hatching in vivo has not been demonstrated in the human 
species. In addition, in the mOllse, where blastocysts hatch in vitro, hatching has never been ob-
served in vivo during a normal pregnancy. The authors report a significant difference in embryo 
implantation rate (EIR) of 23% after assisted hatching compared with 11 % in the control group. 
In a later publication Cohen (19) reported three trials designed to investigate the effect of selective 
assisted hatching by drilling of the zona pellucida of embryos. Patients whose embryos had thick 
zonae (2: 15 lllm) derived a benefit from zona drilling, while embtyos with thin zonae « 13 mm) 
lUay be jeopardized by the procedure. Although more embryos appeared viable in all age groups, 
statistical significance could only be demonstrated in patients above 38 years of age. In this group 
the EIR improved from 3% to 16%. Another report all the improved IVF results after assisted 
hatching in poor prognosis patients confirmed these findings. Schoolcraft et al. (20) defined poor 
prognosis as: basal FSH > 10 mIU/ml, age 2: 39 years or multiple prior IVF failures. In a con-
trolled study 122 embryos underwent assisted hatching. The implantation rate of these embryos 
was high: 33% versus 6% for the 185 non-treated embryos in the control group. This difference 
was highly significant. The incidence of ongoing pregnancy in the assisted hatching group was 
64% compared to 19% in the control group. Earlier implantation after assisted hatching was re-
ported by Liu et a1. (49). The implantation time, calculated by assessing human chorionic go-
nadotrophin serum levels, proved to be significantly shorter in the assisted hatching group. The 
authors postulated that assisted hatching not only enhances embryo implantation by mechanical 
facilitation, but also by allowing earlier embtyo-endometriul11 contact, enabling a higher percent-
age of emblYos to hatch during the critical time-window of implantation. Data on assisted hatch-
ing have mainly been published by Cohen et al. The lack of confirming reports may be due to 
technical difficulties with the procedure itself. Possibly, the potential for embryo damage during 
transfer is increased after assisted hatching, making a gentle atraumatie transfer necessmy (20). 
Trials from other IVF programmes confIrming the efficacy of assisted hatching are needed. 
Another micromanipulative technique, the intracytoplasmic sperm injection (ICSI), will al-
most certainly be introduced in poor responding patients above the age of 40 in order to obtain a 
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high fertilization rate of the few ova obtained. So far no reports on this subject have been pub-
lished. 
Embr)'o transfer polic)' 
The number of emblYos to be transfencd in IVF is stilI a controversial issue. Replacement of a 
higher number of emblYos enhances the chance to obtain a clinical pregnancy in IVF treatment 
(23,50,51). A pregnancy rate of 55% has been reported by Nijs et a!. (51) after replacement of 
four embryos. On the other hand, transfer of a higher number of good quality emblYos leads to an 
increased number of twin and triplet pregnancies (52). Triplet pregnancies should be avoided be-
cause of the social and medical risks for the mother and children (53). Several authors advised 
replacement of two emblYos only in order to avoid triplet pregnancies (21, 22, 51). In these stud-
ies the restricted embryo replacement policy did not affect the pregnancy rates significantly. 
However, in two of these three studies the investigators used an age limit for this policy. Staessen 
et a!. (21) replaced two embryos only when the following criteria were fulfilled: first attempt for 
IVF, less than 37 years old, and good emblYo dcvelopment. Vauthier-Brouzes et a!. (22) uscd the 
age limit of 35 years as one of the criteria. Nijs et a!. (51) mentioned no age limit for replacement 
of the maximum numbcr of two embryos, but in a later paper NUs (52) mentioned an ongoing trial 
with patients> 35 recieving two or three embryos in an altel1late manner. Although replacement 
of only two emblYos appears to be advisable, a lower emblYo implantation rate in higher age 
groups has been reported (23, 24). Thcrefore, the age of the patient could be regarded as one of 
the parameters before a decision on the number of embryos to be transferred is taken. On the other 
hand, a report by Arthur et al. (54) on 1190 consecutive IVF cycles showed no significant differ-
ence in the emblYo implantation rates in different age groups. Replacement of thrce or four em-
bryos in older patients, although possibly indicated to enhance the chances for a pregnancy, wiH 
inevitably lead to high-order pregnancies in some cases and should therefore be discouraged. 
Oocyte donation 
Lutien et a!. (55) reported the first human pregnancy after implantation of a donated ovum and 
proposed the proccdure as treatmcnt of infertiliy due to primaity ovarian failure. Since then sev-
eral indications for this technique have been added. Serhal and Craft (25) extended the use of 00-
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cyte donation (00) to infertile women with a poor response to standard ovulation induction, re-
peatedly fhiled I VF or gamete intrafallopian transfer and to infertile women over forty years of 
age who are still menstruating. Sauer et al. (56) and Abdalla et al. (57) reported the use of OD as 
treatment for women over 40 years old with ovarian failure. In the past few years several reports 
have appeared of programmes accepting recipients for 00 in even higher age groups (58-60). 
Oocyte donation in order to achieve pregnancies in post-menopausal women is controversial and 
ethical aspects have been discussed by Edwards (61) and Antinori (62). 
A survey in the United States showed that 27% of the clinics providing 00 programmes had 
no upper age limit for recipients, while many clinics (31 %) excluded recipients above 40 years of 
age from their programmes (63). 
It has been argued that pregnancy obtained by 00 in older women, may expose the recipient 
to an unacceptable high i-isk. Kirz et al. (64) concluded in a retrospective study that women above 
35 years of age, who are delivered in a modern tertial), care centre, may however be at no higher 
risk of adverse outcome than younger parturients aged 20-25 years. Analysis of data from 511 
pregnancies in women aged 40 or older by Spellacy et al. (65) showed that older women of low 
parity and normal weight can expect a good pregnancy outcome. A retrospective study of the out-
come of pregnancy in 100 primipame aged 40 yeat~ and more by Brassil et al. (66) showed no 
increase in maternal morbidity or perinatal mortality rate. Berkowitz et a1. (67) studied the out-
come of pregnancy in first births in a hospital-based cohort study of 3917 patients with a singleton 
pregnancy. Although women after the age of 35 appeared to have higher rates of complications of 
pregnancy and delivery, their risk of a poor neonatal outcome is not appreciably increased. The 
selection of healthy women as acceptors of donated oocytes may reduce risks (28). Scveral proto-
cols for screening of recipients have been reported (58,60). 
The results of OD programmes have provided important information on the main factors in-
fluencing female fecundity at a later age. Ageing of the uterus has been considered an important 
cause of infertility. Goswamy et al. (68) presented data from an ongoing study to test the hypothe-
sis that poor uterine perfusion is a cause of failure of the implantation of embryos. Feldberg et al. 
(4) suggested that the high abmiion rate in women aftcr the age of 40 years may also be due to 
the ageing uterine enviromnent. In one of the first larger shldies on OD Abdalla et al. (57) found a 
decrease in pregnancy rate in recipients aged 40-49 years. Tn their Shldy the authors could not fmd 
an adverse effect of increasing age of the donors on the pregnancy rate. However, in only 7 out of 
100 donation cycles the oocytes were obtained from donors aged 35 years or more. Other shldies 
only partly confirm the contribution of aging of the utellls to the decline in fecundity with in-
creasing age. Levran et al. (69) found a Significantly lower pregnancy rate in recipients aged over 
33 years in 169 OD cycles. In the same study increasing age of the donor was related to a higher 
miscarriage risk. Yaron et al. (26) retrospectively analysed results of standard IVF and OD in pa-
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tients < 40 and 2': 40 years of age. In standard IYF, clinical pregnancy rates were significantly 
lower in the older patients: 12.9% versus 23.8%. In aD, with no differcnce in dOllor age and all 
donors:; 32 years old, pregnancy rates were also significantly lower in patients above 40 years: 
21.2% versus 29.3%. The authors concluded that the decrcase in endometrial receptivity with age 
is responsible for the highcr rate of implantation failure in older womcn. Howcver, a pregnancy 
rate of 21.2% after 00 in patients aged?: 40 years compared to 12.9% after standard IVF in the 
samc group suggests an effect of ageing of the oocytes. 
Indeed, ageing of the ovaries appears to affect fecundity more than ageing of the uterus. It has 
been demonstrated that when oocytes are obtained from younger donors, the clinical pregnancy 
rate and the embryo implantation rate are high, iuespective of the recipient's age (25, 27, 57, 70). 
Navot et al. (27) rcported results of an oocyte donation programme with donors and recipients 
sharing oocytes from the same cohort. Thiriy-fivc women, aged 40 years or more (mean age 42.7 
± 0.3), who had £1iled to concieve with their O\\'n oocytes recieved oocytes donated by 29 young 
women (mean age 33.4 ± 0.7) undergoing IVF. Clinical pregnancy rates (33% and 40%) and de-
livery rates (23% and 30%) did not differ between donors and recipients. The authors stated that 
the fact that all the viable pregnancies with ovum donation took place after the failure of concep-
tion with own oocytes excludes a negative effect of ageing on endometrial vasculature and uter-
ine blood supply. It thus appears that decreased embryo viability is the main calise of IYF failure 
in patients above 40 years of age. 
The establishment of artificial cycles is to be prefelTcd in aD programmes. Down-regulation 
of the pituitaty gland with GnRH-a until serum levels of gonadotrophins reach basal levels is fol-
lowed by giving oral estradiol valerate to prepare the utcrus. After 15 days, progesterone is added 
in order to establish a secretory endometrium. Using this scheme for steroidal support of the 
utems Edwards et a1. (70) found acyclic women to be more fecund than cyclic women in an aD 
programme. Amenorrhoeic women concieved more frequently, and to higher ages. Serhal and 
Craft (25) and Sauer et a!. (56) also found high pregnancy rates after OD in acyclic women, but 
the number of patients in their studies ,vas limited. A large series of aD in amenolThoeic women 
after steroidal support of the utems was reported by Yaron et a!. (26). In 219 OD cycles 68 preg-
nancies were achieved, giving a pregnancy rate of 31.1 %. This pregnancy rate was significantly 
higher than the 19.7% pregnancy rate in the group of 239 cyclic women. It can therefore be con-
cluded that amenorrhoea maintains a favourable uterus. It has even been suggested that a period 
of induced 3menouhoea might improve the uterine environment in premenopausal women (70). 
In aD programmes the miscarriage rate is directly related to the age of the donor and not to 
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the age of the recipient. Serhal and Craft (25) found only one miscarriage in 12 women older than 
42 years who achieved a pregnancy after OD. Navol et al. (71) reported a 16.7% (2 of 12) preg-
nancy loss in 'vomen aged over 40 who recicvcd oocytes from a dOll or group with a mean age 
30.2 ± 4.9 years. Abdalla et al. (72) described an increasing miscarriage rate with higher donor 
age. \Vhen the age of the dOllor ,vas 35-39 years, the miSCRlTige rate for recipients was 45%. COll-
sidering the higher implantation rates and lower miscarriage rates after OD with oocytcs from 
younger women, OD has been proposed as an alternative for patients with a poor prognosis for 
IVF treatment (25-27). 
Conclusions 
The patient's age, although an indicator of fecundity, should not be the main parameter for 
acceptance of patients for IVF treatment. Results of prestimuiatioll tests like the determination of 
basal FSH level and the clomiphene citrate stimulation test arc morc useful for counselling 
patients before IVF treatment is started. 
Several proposals have been made to improve the results of IVF treatment in patients above 35 
years of age. Controlled ovarian hyperstimulation in older patients with a poor ovarian response is 
still a controversial issue. Contradicting results have been published about the relation between 
dosage of gonadotrophins used and oocyte yield. \\fhen a poor response to ovarian 
hyperstimulation is expected, GnRH-a should only be used in the short flare-up protocol. Assisted 
hatching of emblyos with a thick zona pellucida has been reported to improve the emblYo 
implantation rate. More shldies from other IVF programmes are needed to determine whether this 
technique is beneficial for poor prognosis patients in higher age groups. Replacement of more 
than two emblYos in patients above 35-40 years of age may be indicated in order to enhance the 
chances for a pregnancy. However, the emblyo implantation rate in this patient group in an IVF 
programme should be taken into consideration, since triplet and quadruplet pregnancies have to be 
prevented. Oocyte donation, although controversial in post-menopausal women, seems an 
attractive alternative for IVF patients above the age of 40 who have failed to concieve with their 
own oocytes. The use of oocytes obtained from younger donors gives good results and has 
illustrated the relatively minor role of ageing of the uterus in the decline of female fecundity \vith 
rising age. Better results in OD programmes are obtained with artificial cycles. 
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Chapter 5 
The ovarian response as a predictor for successful in vitro 
fertilization treatment after the age of 40 years 
Fertility alld Sterility 1996; 66:969-73 
Jan Roest\ Al1le Nt van Heusden2, Harold V.H. NIous l, Gerard H. Zeilmakcl..3, Aric Verhoef{'. 
'Department of Obstetrics and Gynaecology, Zuiderziekenhuis, Rotterdam. 'Departmcnt of Ob-
stetrics and Gynaecology, University Hospital Dijkzigt, Rotterdam. 3Departmcnt of 
Endocrinology and Reproduction, Erasmus University, Rotterdam. 
SUllUllal'Y 
To determine whether age or response to controlled ovarian hypcrstimulation (COR) is a better 
predictor of IVF outcome in women 2: 40 years, a retrospective analysis of 2588 consecutive 
cycles ill a transport IVF program was carried out. The correlation bchvecn treatment outcome 
and age, and response to COB was analyzed. The main outcome measure was pregnancy. 
Results: The incidence of poor ovarian response rises significantly with increasing age. 
Analysis of all cycles showed a significant decrease in clinical and ongoing pregnancy rate for 
\vomen ;::: 40 years. Analysis of cycles with a good ovarian response showed no statistically 
significant differences for these parameters behveen womcn ;::: 40 and those younger. A logistic 
regrcssion analysis on pregnancy showed that ovarian response contributes more to the prediction 
of pregnancy than agc. 
Conclusions: Patients aged;::: 40 years with a good response to COH have a good prognosis for 
IVF treatment. Thc age limit for acceptance of patients should not be set at 40 years. Instead, thc 
response to COB can be used to prcdict candidates likely to have a successful IVF outcome. 
Introduction 
In vitro fertilization treatment is time-consuming and stressful for patients. Assisted reproductive 
techniques are expensive and considerable debate exists about \vho will benefit from the 
procedures, and to what extent health insurances should pay for them. For these reasons 
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appropriate patient selection is mandatOlY and a clear indication for treatment must exist. 
Difficulty arises when there is an indication for IVF, but the chances of a successful treatment 
outcome are considered low. Poor IVF results have becn reported in patients above 40 years of 
age (1-4). TIns has led to age limits for acceptance of patients in many programmes. The general 
opinion in IVF programmes in The Netherlands is that patients aged 40 years or older should not 
be offered trcatment. Setting a strict age linnt is debatable. The dctellllination of basal folliclc-
stimulating hormone (PSH) levels (5) and clomiphenc citrate-stimulatcd PSH levels (6) have been 
shmvn to be better predictors of IVF outcome than age. However, pregnancies have becn reported 
in patients with very high basal PSH levels (5,7), indicating that these endocrine screening tests 
are more useful for patient coullselling than for strict patient selection. \Ve hypothesized that 
response to COH might be a good predictor of IVP outcome that can be used prior to follicle 
aspiration. To test this hypothesis, we analyzed the cOiTelation betwecn IVF outcome and age and 
response to COlI in 2588 consecutive cycles of IVP. 
Materials and methods 
Prom the period 1989-1994, the results of2588 consccutive started IVP cycles, can"ied out in the 
transport IVF programme at the Zuiderziekenhuis, were available for analysis. This programme, 
eanied out in cooperation with the IVP laboratOlY at the University Hospital Dijkzigt, has been 
described elsewhere (8). The monitoring of ovarian response during COB was canied out with 
transvaginal ultrasound measurements only (9). No strict age limit for acceptance of patients was 
used. Determination of basal FSH was not done all a routine basis when patients had a regular 
menstrual cycle. Cancellation of started IVF cycles was considered in cases with disappointing 
follicular development during COHo However, strict criteria for cancellation were not used. \"hen 
a better ovarian response in a following cycle was not expected, and the patient felt confident to 
proceed to oocyte retrieval, treatment was continued despite thc relatively poor prognosis. Ninety-
three out of 2588 cycles were cancelled prior to follicle aspiration. In 67 cases the reason for 
cancellation was a poor ovarian response. Follicle aspiration was can-ied out in 2495 cycles. A 
poor ovarian response, defined as the development of::; 3 follicles measuring ~ 15 111111 on the day 
of human chorionic gonadotrophin (HCG) adnnnistration, occurred in 227 out of these 2495 
cycles. 
For initial analysis four different age categories were introduced: patients aged < 30 years 
(group 1), 30-34 ycars (group 2), 35-39 years (group 3) and 2: 40 years (range 40-44, group 4). 
The results of completed IVP cycles in the different groups wcre analyzed for number of patients 
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proceeding to emblYo transfer, oocyte yield, number of emblYos replaced and clinical, ongoing 
and multiple pregnancies achieved. The emblYo implantation rate for the various age categories 
was calculated. To analyse the impact of treatment continuation in IVF cycles with a poor 
prognosis on the overall results of our IVF programme, cycles with a poor ovarian response and 
cycles with a good response were evaluated separately. To test the hypothesis that the ovarian 
response to COB is a better predictor for pregnancy than the patient's age, a logistic regression 
analysis on pregnancy was carried out with age « 40, ~.40) and ovarian response (good, poor) as 
dichotomous variables. 
A clinical pregnancy was defined by a positive urinary test 18 days after oocyte retrieval 
combined with the finding of a gestational sac 2 weeks later. A pregnancy was considered to be 
ongoing when fctal heart motion was observed after 12 weeks of amenonhoea. The results of 
clyopreservation/tha\v cycles were not included in this analysis. For statistical analysis a logistic 
regression analysis was carried out, and Xl test for trend and Student's t-test were used where 
appropriate. P < 0.05 was taken as level of significance. 
Figure 1. Percentages of poor ovarian response and percentages of clinical pregnancies 
(95% confidence intervals) ill completed IVF cycles. 
4~~~----------------------------------------------. 
I 
o - clincal r;oregnancies 
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77 
Results 
The results of all started IVF cycles in the fOllr age groups, irrespective of the ovarian 
response during COH are shown in table I. Out of the 2588 IVF cycles started, 2495 (96%) 
proceeded to oocyte retrieval. The chance for oocyte retrieval and a following embryo transfer 
decreased with rising age. Lower clinical and ongoing pregnancy rates were found with rising 
age: p ~ 0.02 and P ~ 0.007 respectively. The embryo implantation rate appeared to decrease with 
rising age as well: P~O.OOI. The oocyte yield did not differ between groups I and 2, but the 
differences found between groups 2 and 3, and behvecn groups 3 and 4 'vere statistically 
significant: P ~ 0.001 for both. The number of embryos replaced per embryos transfer in group 3 
and 4 were the same. 
Table 1: Results of Started IVF Cycles in the Four Age Groups. 
Age group 2 3 4 P value 
Age (y) <30 30-34 35-39 ".40 
Started cycles 674 1099 646 169 
Cancelled, poor response * 5 (0.8) 20 (1.8) 29 (4.5) 13 (7.7) 0.0001 t 
Oocyte retrievals * 662 (98) 1069 (97) 609 (94) 155 (92) 0.0001 t 
Completed, poor response t 28 (4) 75 (7) 81 (13) 43 (28) O.OOOI-i· 
Embryo transfers t 562 (85) 871 (81) 502 (82) 109 (70) 0.002 t 
Clinical pregnancies t 175(26) 241 (23) 143 (23) 25 (16) 0.02 i· 
Ongoing pregnancies t 144 (22) 200 (19) 113 (19) 17(11) 0.007 t 
Multiple pregnancies § 51 (29) 61 (25) 34 (24) 2 (8) NSII 
Embryo implantation rate (%) 17.0 14.2 12.7 9.2 O.OOlt 
Ooeytes retrieved 11 10.8±7.! 10.2 ± 7.2 8.5 ± 7.2 5.7 ± 4.6 0.001·· 
Embryos transfened 'IH 2.4 ± 0.7 2.6 ± 0.9 2.8 ± 1.0 2.7± 1.0 NS .* 
* Values in parentheses are percentages II NS not significant. 
per started cycle. ~ Values arc means ±SD. 
t X' for trend. ** Student's t-test for difference group 3 and 4. 
t Values ill parentheses are percentages tt Per emblYo transfer. 
per oocyte retrieval. 
§ V~11ues in parentheses are percentages 
of clinical pregnancies. 
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Fewer emblYos were replaced in group I when eomparcd with group 2 (P = 0.03), and in group 2 
comparcd with gl'OUp 3 (P = 0.001). For fhrther illustration the pcreentages of cycles with a poor 
ovarian response and the percentages of clinical pregnancies in completed IVF cycles in the four 
different age categories arc shown in figure 1. 
The results obtained in lVF cycles with development of S 3 follicles measuring 2': 15 mm 011 
the day of HCG administration are shown in table 2. Except for the percentage of emblYo 
transfers (P = 0.014), no statistically significant differences were fotll1d betwcCll the age 
categories. The 43 oocyte retrievals in group 4 resulted in one ongoing pregnancy only. 
Results obtained in the four age groups for completed cycles with a good ovarian response to 
COB arc shown in table 3. No statistically significant differences were found between the age 
groups for percentages of patients who proceeded to cmblYo transfer and for clinical and ongoing 
pregnancy rates. The embryo implantation rate decreased significantly with increasing agc. 
Statistically sigllificallt differences for oocyte yield were found between groups 2 and 3 (P = 
0.001), and betweell groups 3 and 4 (P = 0.001). With rising age morc embryos were replaecd per 
embryo trallsfer, giving significallt differences between groups I and 2 (P = 0.001) alld bel\veell 
groups 2 and 3 (P = 0.001). 
Table 2: Results of Completed lVF Cycles with a Poor Ovariall Responsc. 
Age group 2 
Age (y) <30 30-34 
Oocytc retrievals 28 75 
Embryo transfers * 19 (68) 53 (71) 
Clinical pregnancies * 5 (18) 8 (II) 
Ongoing pregnancies * 5 (18) 6 (8) 
Embryo implantation rate (%) 18.7 11.1 
Oocytes retrieved j: 2.1 ± l.l 1.9 ± 0.8 
EmblYos transferrcd til 1.7 ± 0.7 1.5 ± 0.6 
* Values in parentheses are percentages per oocyte retrieval. 
t X' for trend. 
t Values arc means ± SD. 
§ Studellt's t-test for differences between groups 3 and 4. 
II Per embryo transfer. 
3 
35-39 
81 
52 (64) 
11 (14) 
8 (10) 
14.3 
1.8 ± 1.1 
1.6 ± 0.7 
4 
2':40 
43 
19 (44) 
3 (7) 
I (2) 
9.4 
1.5 ± l.l 
1.7 ± 0.7 
P value 
0.014t 
NSt 
NSt 
NSt 
NS§ 
NS§ 
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The percentages of clinical pregnancies in relation to age (age as a categorical variable 
dichotomized at 40) and ovarian response (good, poor) are shown in table 4. 
The results of a logistic regression analysis on pregnancy ,vitlI the dichotomous variables 
ovarian response (good, poor) and age « 40,:>' 40) are shown ill table 5. 
Table 3: Results of Completed IVF Cycles with a Good Ovarian Response. 
Age group 2 
Age (y) <30 30-34 
Oocyte retrievals 634 994 
EmblYo transfers * 543 (87) 818 (82) 
Clinical pregnancies * 170 (27) 233 (23) 
Ongoing pregnancies ~ 139 (22) 194 (20) 
Embryo implantation rate (%) 17.0 14.3 
Oocytes retrieved t 11.2 ± 7.0 10.8±7.1 
Embryos replaced til 2.5 ± 0.7 2.6 ± 0.9 
* Values in parentheses arc percentages per oocytc retrieval. 
t x' for trend. 
t Values are means ± SD. 
§ Student's t-test for differences between groups 3 and 4. 
II Per embryo transfer. 
3 
35-39 
528 
450 (85) 
132 (25) 
105 (20) 
12.6 
9.5 ± 7.2 
2.9 ± 0.9 
4 
:>.40 
112 
90 (80) 
22 (20) 
16 (14) 
9.2 
7.3 ±4.5 
2.9 ± 1.0 
P value 
NSt 
NSt 
NSt 
O.OOlt 
0.001 § 
0.001 § 
Table 4: Clinical Pregnancies after IVF Treatment in Relation to Age « 40 years,:>, 40 years) 
and Ovarian Response (Good, Poor). 
Age Response Oocyte retrievals Clinical pregnancies ~ 
< 40 Good 2156 535 (24.8) 
<40 Poor 184 24 (13.0) 
:>. 40 Good 112 22 (19.6) 
:>. 40 Poor 43 3 (7.0) 
* Values in parentheses are percentages per oocyte retrieval 
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Table 5: Logistic Regression Model. 
Age 
Ovarian response 
Discussion 
Regression 
coefficient (b) 
-0.36 
-0.83 
Standard 
enol' 
0.23 
0.21 
P value 
0.12 
0.0001 
Odds ratio 95% confi-
dence interval 
0.70 0.44-1.09 
0.44 0.29-0.66 
For appropriate patient selection and cOllllselling, predictive tests for a patient's individual 
performance in IVF treatment arc needed. Tests with a high predictive value could give patients 
and physicians realistic expectations of the chances for pregnancy. Ideally, these tests should also 
allow identification of patients who are destined for treatment failure and thus should not undergo 
the procedure. However, the methods used for identification of patients with a pDQr prognosis for 
successful outcome of IVF treatment arc controversiaL It is recognised that advanced age is 
correlated with reduced chances for pregnancy after IVF. This has led to the use of age limits for 
IVF treatment. Strict age limits for IVF are debatable. Screening cndocrinc tests, like the 
determination of basal (5) and clomiphenc citrate-stimulated (6) FSH levels have been proposed 
and proved to have a bettcr predictive value for IVF treatment outcome than the patient's age. A 
cOlTelation between higher basal FSH levels and 100ver pregnancy rates aftcr IVF has been 
reported. Toncr et al. (5) found no ongoing pregnancies in patients with a basal FSH > 25 
mTU/mL. However, the same authors reported an ongoing pregnancy rate of 15% for patients with 
a basal FSH of 20 mlU/mL. Licciardi ct al. (7) found no pregnancies in patients having cycle day 
3 FSH levels of> 17 mlU/mL and estradiol (E,) > 45 pg/mL, but in patients with E, levels <: 45 
pg/mL and a basal FSH > 17 mTU/mL, an ongoing pregnancy rate of 16.7% was reported. 
Apparently, in patient groups with a considerable elevation of basal FSH, pregnancy rates are 
found that can still be considered acceptable. These findings indicate that screening endocrine 
prestimulation tests arc useful for patient counse1ling, but should be used \vith care for patient 
selection. Screening tests will pick up some patients with velY high FSH levels who could be 
predicted not to respond to ovarian hyperstimuiation, but moderate FSH elevations should not be 
a reason to witWlold therapy. It therefore seems approprinte to use the outcome of COH as an 
indicator for success. In this way the decision whether to complete IVF treatment, including the 
more stressful and expensive part of IVF treatment: oocyte rctrieval, laboratOlY phase and embtyo 
transfer, is further individualized. \Vhen considering thc cost of IVF treatment, differences 
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between countries should be kept in mind. Especially the prices of the gonadotrophins can vmy 
considerably. 
fn the IVF programme at the Zuiderziekenhuis no strict age limit is used and no standard 
endocrine screening tests are catTied out. Premenopausal patients with an indication for IVF 
treatment are given an IVF trial. "'hen during COH a poor ovarian response occurs, the patient is 
informed about the relatively poor prognosis, and, if the patient so chooses, follicle aspiration is 
catTied out. The definition of poor response used was in line with criteria mentioned by other 
authors (10-12). Of all started cycles only 2.7% were cancelled because of a poor ovarian 
response. As a result, a relatively large group of patients with a poor ovarian response to COH 
proceeded to follicle aspiration. This enabled us to test the hypothesis that ovarian response is a 
better predictor for successful IVF outcome than age. 
Analysis of the trcatment outcome of all IVF cycles showed that the rates for clinical and 
ongoing pregnancies in higher age groups were significantly lower. To detennine whether this 
was caused by a high proportion of IVF cycles with a poor ovarian response in the higher age 
groups, we distinguished between poor and good responders to COH and evaluated the results in 
the two groups separately. As expected, the results of the poor responders show that poor ovarian 
response is associated with a poor treatment outcome. Continuation of treatment seemed 
worthwhile in patients below 30 years of age since in this group 28 oocyte rctrievals lcd to 5 
ongoing pregnancies, giving an 18% ongoing pregnancy rate. However, betwcen 30 and 40 years 
of age the results were poor. There appeared to be hardly any justification for continuation of 
treatment for patients ,,,ith a poor ovarian response aged ~ 40. Forty-three oocyte retrievals led to 
only one ongoing pregnancy. In patients aged ~ 40 with a good ovarian response to COB, the 
outcome of IVF treatment did not differ significantly from the results in the younger age groups. 
The oocyte yield was smaller, and the embryo implantation rate 100ver with rising age, but the 
ongoing pregnancy rate did not decline significantly. Rising age correlated ,,,jth an increasing 
incidence of poor ovarian response. The percentages of poor responders found in the four age 
groups corresponded well with the discharge rates during stimulation reported by \\'ood et a1. 
(13). 
A logistic regression analysis on pregnancy ,,·,rith ovarian response (good, poor) and age «40, 
~40) as dichotomous variables confinned that ovarian response is a better predictor for IVF 
treatment outcome than age. \Vhen age of the female partncr and ovarian response were included 
in the logistic regression, the likelihood of pregnancy with poor ovarian response was 0.44, (95% 
confidence interval 0.29-0.66) (P~O.OOOl), and the likelihood of pregnancy over the age of 40 
was 0.70, (95% confidence interval 0.44-1.09) (P=O.12). 
In conclusion; this study shows that ovarian response is a better predictor for sliccessfullVF 
treatment than age. Patients aged ~ 40 with a good ovarian response to COI-I have a good 
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prognosis for IVF treatment. Therefore, thc agc limit for IVF treatment should not be set at 40 
years, When :s 3 follicles with a diameter:> 15 mm develop during COlI, cancellation of the I VF 
cycle is justificd, especially in the older patients. The result of COH can be used to counsel and 
select patients before the more stressful and expensive phase of IVF treatment starts. 
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Chapter 6 
Treatment policy after poor fertilization in the first IVF cycle 
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Summary 
Patients with poor fertilization (PF ~ fcrtilization of S 20% of all oocytes) in their first IVF cycle 
were followed in the subsequent cycle to assess the chance of recurrence of this phenomenon. In 
cases of PF, a differentiation was made between total fertilization failure (TFF), and low 
fertilization rate (LFR) dcfined as fertilization of> 0% and S 20% of all oocytcs. Aftcr analysis of 
the relation between occurrence of TFF and the number of aocytcs retrieved, TFF was defined as 
fertilization failure in cycles with 2: 4 oocytcs obtained. Based on the relation between the 
fCliilization rate and the number of motile spenn cells/mL semen in the first cycle, patients were 
divided into 3 subgroups with different sperm parameters; group 1: < 5x10~ motile sperm 
cells/mL, group 2: 5-19xI0' motile sperm cells/mL, and group 3::> 20x10' motile sperm cells/mL 
in the ejaculate. Patients with a TFF or LFR in the first cycle who continued treatment, were 
followed in the subsequent cycle. The chance of occurrcnce ofTFF or LFR in the second cycle in 
the 3 groups was assessed. The rCCUlTence rate ofTFF was high: 45 - 70%, and PF occurred in 50 
- 75% of all cases. Similarly, after LFR in the first cycle, TFF and PF frequently occUlTed in the 
second cycle: 37% and 50% rcspectively. 
In conclusion: In our population, both TFF and LFR in the fIrst IVF cycle has a high chance of 
recurrence in the subsequent cycle. It appears that TFF is not a separate entity, but the severest 
form of PF. Consequently) in our population) ICSI should be considered after PF in the first cycle, 
especially in cases \vith a small oocyte yield. 
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Introduction 
The incidence of total fertilization failure (TFF) and its predictive significancc for subsequent IVF 
cycles has been reported by several authors (1-5). In contrast, the incidence of low fertilization 
rate (LFR) in an IVF cycle and its significance for the treatment prognosis has not been given 
much attention. Apparently, when after LFR one or more embryos me available for replacement, 
and, consequently, a true chance for pregnancy exists, the IVF attempt is seen as successful. 
However, if TFF and LFR are both expressions of a defective interaction between oocyte and 
Spel111 cell, the recurrence rate in a subsequent cycle and the treatment prognosis of LFR and TFF 
could be compnrable. 
The chance of recurrence ofTFF in a subsequent cycle as reported by others is approximately 
20%, irrespective of the indication for IVF (1-5). Because of this low recurrence rate, it has been 
advised to undertake 2 more IVF attempts before reverting to other therapeutic options like the 
use of donor sperm or micromanipulative techniques (3, 5). However, with the introduction of 
intracytoplasmic sperm injection (ICSI), a micro manipulative technique has become available that 
has proved to be a good alternative after TFF. For ICS[ a TFF rate of 3% only has been reported 
(6). 
[n this shldy the chance of successful fertilization in a subsequent IVF cycle after TFF or LFR 
in the first cycle is assessed. The aim of the shldy was to investigate whether TFF and LFR in the 
first IVF cycle are indications for assisted fertilization in following cycles. 
iHatel'ials and methods 
Patients with poor fertilization (PF ~ fertilization of", 20% of all oocytes) in their first [VF cycles 
who continued treatment, were followed in the subsequent cycle. In cases of PF, a differentiation 
was made between TFF and LFR, defined as fertilization of> 0% and::; 20% of all oocytes. In 
IVF cycles with a small oocyte yield, TFF can be seen as a chance OCCUlTence in a substantial 
number of cases. Consequently, to define TFF, an analysis of the relation between the chance of 
occurrence of TFF and the number of oocytes retrieved was calTied out. As rep0l1ed previously, 
the average fertilization rate per oocyte ill the population of the transport IVF programme is 50% 
(7). The a priori chance ofTFF in relation to the number of oocytes retrieved is indicated in figure 
I. The actual incidence of TFF in the popUlation shldied is also indicated in this figure. Based on 
the data obtained, TFF was defined as fertilization failure in cycles with;::: 4 oocytes retrieved. 
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To divide patients into subgroups with different chances of fertilization, the relation between 
the chance of an oocyte being fertilized and thc number of motile sperm cells/mL in the semen 
used, was analysed for 1211 consecutive first IVF cycles. Three subgroups were defined for 
separate analysis. 
In 1049 out of 1211 patients:> 4 ooeytes were retrieved in the first IVF cycle. Of these, 207 
had a poor fertilization in the fiTSt cycle, and 119 proceeded to a second attempt. In the second 
IVF cycle, 3 patients had < 4 oocytes retrieved and were excluded from the study, leaving 116 
patients for further analysis. The second cycles of the patients in the 3 subgroups with TFF or 
LFR in the first IVF cycle were analysed scparately, and thc chance of recurrence of poor 
fertilization in the sccond cycle was studied. 
Results 
The theoretical incidence of TFF as a chance OCClllTenCC, and the achml incidence of TFF in 
relation to the number of oocytes retrieved in the first TVF cycle, are shown in figure 1. 
Figure 1. 
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As the number of retrieved oocytcs increases, the incidence of TFF as the result of chance 
OCCUlTenccs decreases. The observed incidence in cycles with 4 oocytes retrieved was 16%, while 
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the theoretical incidence ofTFF in these cycles was 6%. For further analysis TFF in cycles with ~ 
4 oocytes was considered as indicative of a defective interaction betwecn oocytc and sperm cell. 
Consequently, all patients with < 4 Docytes retrieved in the first IVF cycle were excluded from 
further analysis. 
Figure 2. Relation between fertilization rate and the number of motile sperm cclls/mL scmen. 
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The relation behveen the chance of fertilization per oocytc and the number of motile sperm 
cells/mL semen (median and 25-75 percentiles) is shown in figure 2. Based on this graph 3 
subgroups were distinguished; group I: < 5x10' motile sperm cells/mL, group 2: 5-19xlO' motile 
sperm cells/mL, and group 3: 2' 20x10' motile sperm cells/mL. 
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The incidences of TFF in the first IVF cycle and the chance of recurrence of TFF and 
occurrence of LFR in the subsequent cycle are shown in table l. The last colunm of the table 
shows thc cases with poor fertilization (PF). The recunence rate of TFF in the subsequent cycle 
was high in the 3 groups. Poor fertilization occurred in 60% of all cycles following TFF. 
Table 1. Total Fertilization Failure in the First Cycle and Poor Fertilization in the Second Cycle 
in the 3 Groups. 
TFF l"cycle Continued 
(*) (t) 
TFFW 
Group 1 (n~196) 39 (20%) 20 14 (70%) 
Group 2 (n~232) 46 (20%) 20 8 (40%) 
Group 3 (n~621 ) 51 ( 8%) 38 17 (45%) 
Total (n~1049) 136 (13%) 78 39 (50%) 
* Percentage of TFF in the group in the first cycle. 
t Patients with < 4 Docytes in the second cycle (n = 3) were excluded. 
t Percentage of patients who continued after TFF in the first cycle. 
Second 
cycle 
LFR(t) PFm 
1 (5%) 15 (75%) 
5 (25%) 13 (65%) 
2 (5%) 19 (50%) 
8 (10%) 47 (60%) 
The results of subsequent cycles of patients with a low fertilization rate in the first cycle are 
shown in table 2. Total fertilization failure in a second cycle occurred frequently (37%) after LFR 
in the first IVF attempt. Poor fertilization occUlTed in 50% of all subsequent cycles. 
Table 2. Low Fertilization Rate in thc Fil~t Cycle and Poor Fertilization in the Second Cycle in 
the 3 Groups. 
LFR 1st cycle Continued Second cycle 
TFF (*) LFR (*) PF (*) 
Group 1 8 2 1 (50%) (50%) 
Group 2 27 13 6 (46%) 2 (15%) 8 (61%) 
Group 3 36 23 7 (30%) 3 (13%) 10 (43%) 
Total 71 38 14 (37%) 5 (13%) 19 (50%) 
* Percentage of patients \vho continued after LFR in the flrst cycle. 
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Discussion 
Although low fertilization rates have been reported as an indication for the use of 
micromanipulativc techniques (8), the incidence of LFR in !VF has not been givcn much 
attention. In contrast, the incidence ofTFF, and the treatment policy after TFF has been discussed 
by several authors. The 1110st frequently given advice is to tty conventional IVF treatment again 
for a second or even a third trial without resorting to assisted fertilization using lllicro~ 
manipulative tcchniques (3-5). The advice given by these authors is mainly based on the low 
recurrence rate for TFF found in their studies. However, the definition of TFF used in these 
studies can be questioned. Failure of fertilization in cycles with only few oocytes retrieved can be 
seen as a chance occurrence. In many of these cases there might be no abnonnality in the 
interaction between Spel1ll cell and oocyte. Therefore, based on the incidences of TFF in cycles 
with a 10\" number of oocytes in our study, we excluded patients with < 4 oocytes retrieved in 
their first IVF cycle from the analysis. Using this approach, we idcntified a subpopulation of 
patients with a reCUlTence rate ofTFF in a second IVF cycle of 50% as shown in table 1. This rate 
is high when compared with other reports (1-5). When the cases of LFR in the second cycle were 
included, the incidence of PF in the second cycle was 60%. The introduction of subgroups with 
different sperm parameters showed a comparable poor prognosis for all 3 groups. 
The results shown in the tables 1 and 2 appear to indicate that thcre is no essential difference 
between the mechanisms ofTFF and LFR. After LFR in the first cycle 37% of patients had a TFF 
in the subsequent cycle, and 50% of the patients \vho continued with IVF treatment had a PF in 
the second cycle. It seems that in the population studied LFR in the first cycle has a similar poor 
prognosis as TFF. Apparently, TFF should not be regarded as a separate entity inlVF. 
With the availability of intracytoplasmic spenn injection (ICSI) the therapeutic options for 
defective interaction between sperm cell and oocyte have improved considerably. The results of 
ICSI are good when compared with other 111icromanipulative techniques like subzonal 
insemination (9) or partial dissection of the zona pellucida (10). The results obtained in the 
population studied point out that ICSI might be indicated after TFF in the first IVF cycle. The 
high recurrence rate ofLFR shows that the use of ICS! could even be considered after LFR in the 
first cycle, especially when few oocytes are expected to be retrieved. 
In conclusion, in our population total fCl1ilization failure and low fertilization rate both have a 
high recurrence rate. The use ofICS! should therefore be considered after poor fertilization in the 
first cycle. 
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Chapter 7 
The incidence of major clinical complications in a transport IVF 
programme 
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SUlllluary 
Four different major clinical complications are identified in a retrospective analysis of 2495 IVF 
cycles resulting in oocyte retrieval. The severe form of ovarian hyperstimulation syndrome 
(OHSS) occurred in 18 patients, giving a prevalence for this complication of 0.7%. Seven (39%) 
out of these 18 patients were previously diagnosed as having polycystic ovaries. Eleven patients 
were admitted with moderate OI-ISS. Adnexal torsion was diagnosed in two patients. Ovariectomy 
was considered necessmy in both cases. Complications of the transvaginal procedure occurred in 
7 cases (0.3%); one patient bad an acute apcndicitis with punchu'c holes in the appendLx, 6 
patients were admitted shortly after oocyte retrieval with a pelvic inflammatory disease (PID). 
Thirteen out of the 624 pregnancies obtained werc ectopics, giving an ectopic pregnany rate of 
2.1 %. It is concluded that serious clinical complications of IVF treatment are rare. However, 
patients should be counselled for the occurrence of serious procedure-related complications before 
entering an IVF programme. 
Introduction 
In vitro fel1ilization treatment is an elective procemu'C. Clinical complications caused by the 
procedure are thercfore always iatrogenic. Although complications are reported to occur 
infrequently, counselling of patients on possible complications of IVF treatment is neceSS81Y 
before infonned consent can be signed. The incidence of complications appears to differ between 
programmes and could dcpend on various factors like: methods used for controlled ovarian 
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hyperstinmlation (COH), criteria lIsed for cancellation of cycles, and techniques uscd for follicle 
aspiration and emblYo transfer. Therefore it seems advisable to inform patients about the 
incidence of clinical complications in the velY IVF programme they are about to join. To obtain 
data concerning the incidence of clinical complications leading to hospital admission in our 
transpOit IVF programme a retrospective analysis is carried out. In the population studied, four 
different major complications are identified: ovarian hyperstimulation syndrome (OHSS), adnexal 
torsion, pelvic inflall1matOlY disease (PID) and ectopic pregnancy. The occurrence of high-order 
pregnancies is not discussed since this ,,,ill be the subject of a separate paper. Detailed reports 
have been published on the occunence of a hepatitis-B infection related to the rVF-laboratOlY 
procedure (1). Publications on assisted reproduction including information concerning 
complications are reviewed, and the findings of our retrospective study are compared with these 
reports. 
I\'Iatcrials and methods 
In a retrospcctive analysis of 2495 consecutive cycles resulting in oocyte retrieval, the incidence 
of major clinical complications of IVF treatment is assessed. A major complication is defined as a 
complication resulting from IVF treatment leading to hospital admission. The organizational 
aspects of ollr transport IVF programme with satellite clinics has been described previously (2). 
Patients ,vere accepted for the programme after serological tests (HBsAg, syphilis, human 
immunodeficiency virus) and routine physical examination. Controlled ovarian hyperstimulation 
consisted of human menopausal gonadotrophin (HMO) 150-450 IU i.m./day (Humegon'; 
Organon, Oss, The Netherlands), depending on age, and starting on cycle day 3. The standard 
starting dose of HMO for patients aged below 35 years was 150 IU/day, above this age 225 
IU/day was used. Patients diagnosed as having polycystic ovaries, or known with a previous 
explosive ovarian response during COB started with 75-150 IU/day. Since the introduction of 
gonadotrophin-releasing hormone agonists (OnRI-I-a), the short flare-up regime \vas used in most 
cases, starting on cycle day 1 until the day of human chorionic gonadotrophin (HCG) injection. 
Plasma estradiol (El) measurements ,,,ere not calTicd out during COHo rV[onitoring of follicle 
growth was performed by vaginal ultrasound measurements only. \Vhen > 35 developing follicles 
were seen during monitoring, the cycle \vas cancelled; in most cases by withholding HCG and 
continuing OnRR-a to reduce the chance of development of OHSS. Oocyte retrieval was planned 
35 hours after i.Ill. injection of 10 000 IU ReO (PregnyF; Organon) on the day the Icading 
follicles reached a diameter of 18-20 Illlll. 
96 
Follicle aspiration was carried out by ultrasound-guided vaginal puncture under local 
anaesthesia. Preventive antibiotics were not used. Chemical desinfection of the vagina was not 
used in view of possible hann to the oocytes. Before oocyte aspiration the vagina \vas soaked 
twice with sterile isotonic saline solution. The ultrasound transducer was covered with a sterile 
plastic sheet. The paticnt was covered with a sterile, single-use surgical sheet, the gynaecologist 
uscd sterile surgical gloves. Bilateral ovarian punchlre was carried out with the same one-way 
needle. Evacuated follicles were not rinsed. Luteal support was given with 1500 IU HCG 011 the 
day of ovum retrieval (day 0) and all days 3, 6 alld 9. When 0> 15 follicles were retrieved, 
progestcrone (200 mg vaginally twice daily; Progestan"i-; Organon) was prescribed for 15 days. In 
these cases HCG for lutcal support was withheld. Replacement of embryos was calTied out 2 to 5 
days after oocyte retrieval. Emblyos (initially a maximum of fOUl') were replaced to the midcavity 
position. The amount of culhlre fluid used varied from 30 - 60 ml. No routine consultation was 
planned during the first 2 weeks after embryo transfer. Patients were instructed to contact the 
clinic in case signs and symptOl~ls of possible complications occurred. For the classitication of 
OHSS the classification of Golan (3) was used. All patients with a severe OHSS or with signs of 
PID were routinely admitted for clinical observation and treatment. 
Ovarian hypcrstimulation syndrome 
The severe form of OHSS was diagnosed in 18 patients, giving a prevalence per oocyte retrieval 
of 0.7%. l\velve cases were diagnosed as grade 4, 6 cases were grade 5. The median length of 
hospital stay was 11 days, range 4-25 days. Five patients underwent abdominal paracentesis for 
relief of symptoms. Tn one case with extensive pleuw.l effusion, bilateral thoracal drainage was 
necessary. In 13 out of 18 patients (72%), the NF cycle resulted in a pregnancy; 2 triplets alld 7 
twins, giving a multiple pregnancy rate of 69%. Although moderate OHSS was not routinely 
followed by hospital admission, 11 patients with this condition were admitted. The median 
duration of admission for moderate OHSS WllS 8 days, range 4-12 days. Four patients (36%) were 
pregnant, all multiple pregnancies; 2 triplets and 2 t\"ins. 
The ovarian hyperstimulation syndrome is the most frequent complication of COHo Rep0l1s of 
OHSS developing after all methods of ovulation induction have been published (4). In rare cases, 
the severe form of OHSS can result in a life-threatening condition (5). The characteristic clinical 
components of OI-ISS are ovarian enlargement with mUltiple cyst formation and oedema of the 
stromll, and an acute fluid shift from the intravascular space to the extravascular compartment, 
associated with ascites, hydrothorax and generalised tissue oedema. The latter component of the 
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syndrome is the main cause of the morbidity and mortality related to it. The fluid accumulation in 
the peritoneal and pleural cavities leads to hypovolemia and hemoconcentration. "'ithout 
cOlTection, renal perfusion can be modified with resultant oliguria. Increased hemoconcentration 
may lead to thrombosis and thromboembolism. 
Classification 
The lirst classification of the OHSS was introduced by Raban et al. (6), later modified by 
Schenker and Weinstein (4). This classification divided the syndrome in three clinical stages: 
mild, moderate and severe, and six grades. "'hen ovarian stimulation is carried out for assisted 
reproductive techniques (ART), mild hyperstimuiation, allowing recruitment of a cohort of 
mature follicles, is a prill131Y goal of the treatment. As a result, the 'mild' OHSS, as proposed by 
Rabau et aI., is part of almost evelY stimulation cycle for IVF. In the absence of clinical 
symptoms it has no clinical value and should not be seen as a complication. Therefore, Golan et 
a1. (3) proposed a new classification as shown in table 1. 
Pathogenesis 
The pathogenesis of OHSS is still poorly understood. Several mediators for the pathogenesis have 
been proposed. Estradiol does not seem to play an important role in the pathogenesis of OHSS. 
Estradiol is a marker for the ovarian response, not the causative agent in OHSS (7). Pellieer et aI. 
(8) rep0l1ed moderate to severe OHSS in a woman ,,,ith a partial 17,20~desmolase deficiency and 
vely low senUll E2 levels. 
Polishuk and Schenker (9) stated that the development of ascites is secondalY to the increase 
of capilJaIy permeability of the peritoneum mediated by a vaso-aetive substance secreted by the 
ovaries. The rapid ovarian growth requires extensive angiogenesis which itself is associated with 
an increase in capillary penlleability. Frederick et al. (IO) showed the agent(s) required for this 
neovascularization to be present in human follicles measuring > 16 mm diameter by 
demonstrating angiogenesis in the rabbit comca after injection of human follicular fluid. 
Fernandez et al. (IJ) found high renin-like activity in preowlatOlY follicular fluid. This, and the 
demonstration of a correlation between plasma renin activity and severity of OHSS (12), led to 
the theOlY that these substances play an important role in the pathogenesis of the syndrome. l\10re 
evidence ,vas found indicating that activation of the rcnin-angiotensin-aldosterone system is a 
primary event in OHSS and not merely the consequence of plasllla volume concentration (13). 
Very high plasma levels of active renin and aldosterone were found in patients \"ith severe OHSS, 
,,,blch were not suppressed when the extracellular c0ll1pat1ments were greatly expanded. The 
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values subsequently declined to normal levels, despite the use of diuretics, suggesting that the 
renin was of non-renal origin since its production was apparently unaffected by influences which 
control renal juxtaglomerular secretioll. 
Table t. Clinical Classification of Ovarian Hyperstimuiation. 
Classification 
Mild 
Moderate 
Severe 
Grade 
2 
3 
4 
5 
Symptoms 
Abdominal distension and discomfort 
Grade 1 + nausea, vomiting and/or dialThea, ovaries < 12 cm 
tvlild + ultrasonic evidence of ascites 
:Moderate + clinical evidence of ascites and/or hydrothorax or 
breathing difficulties 
All the above + increased blood viscosity due to 
hemoconcentration, coagulation abnol1nalitics, diminished 
renal perfusion and function 
Prostaglandins arc other vasoactive substances proposed as possible mediators in the 
development of OHSS. However, the administration of indomethacin (14) had no influence on 
ascites fOI1nation in animal experiments. Histamine is another substance that has been evaluated 
as a possible mediator. Although the use of histamine-receptor blockers in animal studies yielded 
promising results in reduction of ascites and ovarian size in OHSS, later studies failed to detect a 
role for histamine in the pathogenesis (15). 
Prevalence and factors influencing the incidence of OHSS after ovarian stimulation 
In IVF treatmellt, tbe development of mild ovarian hyperstimuiation, allowing recruitment of a 
cobort of mature follicles, is a primary goal. The incidence of severe OI-ISS is relatively rare in 
patients undergoing ovarian stimulation for IVF when compared "\vith ovulation induction cycles. 
Schenker and "'einstein (4) reported the occurrence of severe OI-ISS after ovarian stimulation for 
ovulation induction in approximately 2% of the cycles. The incidence of severe OHSS after COH 
ranges /i·0I11 0.5 to 1.8% (16-21). The prevalence of 0.7% found in ollr population is comparable 
with these reports. Punchlre and aspiration of the ovarian follicles is apparently an effective way 
to avoid ovarian hyperstimulation (3). 
Several factors have been reported to influence the incidence of OHSS. The importance of 
polycystic ovaries (PCO) as a risk factor has been stressed (4,19,22,23). Among the 18 patients 
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with severe OHSS in our population, 7 (39%) had been diagnosed as having polycystic ovaries. A 
high ovarian response during COH, resulting in a high oocyte yield, is associated with a higher 
incidence of OHSS (23-25). An increased prevalencc of OHSS is seen when GnRH-a is used 
during COH (19, 26, 27). The administration of ovulatory HCG has been proposed as the most 
important factor in inducing OHSS (17, 23). The pregnancy rate in OHSS cycles is reported to be 
3-4 times higher when compared to cycles without signs of hyperstimulation (26). Oocyte donors 
in donor I)rogrammes have a velY low risk of OHSS, probably becausc of the absence of 
pregnancy after COH (28). These repmis suggest a positive role of endogenous HCG in the 
development of OHSS. Dahl Lyons et a!. (29) differentiated between early OIISS, presenting 3-7 
days after HCG administration, and late OHSS, presenting 12-17 days after HCG administration. 
Early OHSS was predicted by the number of oocytes retrieved and the E2 concentration 011 the day 
of HCG administration, while late OHSS correlated with the number of gestational sacs seen on 
ultrasound 4 weeks after emblYo transfer. The authors concluded that carly OHSS was an effect 
of the HCG administered prior to oocytc retrieval, whereas late OHSS was induced by the rising 
semm concentration of HCG produced by the early pregnancy. In case a high ovarian response 
occurs, the usc of exogenous HCG for luteal phasc supplementation increases the risk of 
development of OHSS (22). 
Prevention of OHSS 
Several methods have been proposed to lowcr the incidence of OHSS. Patients who previously 
developed OHSS, or who are known to have PCO, should be treated with a low-dose 
gonadotrophin protocol (19, 22). In our IVF program, patients with PCO are treated with 2 
ampoules (150 U) HMG daily, patients who previously had OHSS with 1-2 ampoules. The 
condition did not recur in the severe form in the same patient. 
Estradiol peak level and rate of increase during COH, numbcr and size of follicles developing, 
and number of oocytes collected are paramcters used for prediction of the development of OHSS. 
In view of this, close monitoring of COH as a mcthod for prevention has been advised (22). 
However, a considerable overlap of distribution of these values behveen OHSS and control 
populations has becn found (24). Therefore, the value of intensive monitoring for prevention of 
mISS has been debated (30, 31). 
Nlonitoring for impending OHSS is carried out by transvaginal ultrasound examination, 
frequently combined with measurcments of scrum E2 concentration during COHo In case an 
explosive ovarian response occurs, ovulatOlY HCG can be withheld and thc IVF cycle cancelled. 
However, precise criteria for impending OlISS and subsequent cancellation of the IVF cycle are 
lacking. There is wide variation between authors in the E2 levels above which they advise HCG to 
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be withheld. Fonnan et a1. (27) withheld HCG at an E, serum level> 2000 pg/m1. In these cases 
the administration of gonadotrophins was stopped and GnRB-a continued. After a period of 
desensitization follicular stimulation was recommenced with a lower dose of gonadotrophins. 
Other authors (32) developed less strict criteria, and reported that cycles with E, levels co 5000 
pg/ml need not be cancelled and can proceed to oocyte rccovelY and cmblYo transfer. NIorris et al. 
(28) found only one case of OHSS among 10 paticnts with E, concentration> 6000 pg/mJ and> 
30 oocytes recovered. The authors concluded that the risk of OHSS at high levels of stimulation is 
lower than previously believed. In contrast, Asch et a1. (33) found OHSS in 80% of the patients 
with peak levels> 6000 pg/ml and> 30 oocytes collected. Thc same authors found no cases of 
OHSS with serum E, Icvels < 3500 pg/ml, and only one case in a group of 67 paticnts with levels 
between 3500 and 6000 pg/m1. 
In several IVF progranmles monitoring of COH is carried out by transvaginal ultrasound 
examinations only (2, 30, 34). Tn these programmes the number of developing follicles is used as 
criterion to cancel the cycles or proceed to oocyte retrieval. The development of more than 30-35 
follicles, corresponding witb a scrum E, level of approximately 6000 pg/ml (33), has been 
mentioned as criterion for cancellation (25,31). 
Besides cancellation of the cycle, several other approaches are possible in cases of impending 
OHSS. Withholding thc O\QIlatory dose ofHCG is one option. It was hypothesized tbat the longer 
half-life, higher affinity and longer intracellular effect of exogenous HCG compared to 
endogenous HCG results in a more extensive luteinization of hyperstimulated ovaries. Therefore, 
Gonen et a1. (35) used the initial flare-up effect of GnRH-a to achievc the final follicle maturation. 
The discontinuation of gonadotrophin therapy and deferring HCG administration until the plasma 
El concentration drops below 3000 pg/llll, called "prolonged coasting", has also been proposed 
(25). 
Elective clyoprcservation of all embryos of patients at high risk of development of OHSS, to 
avoid a pregnancy and subsequent production of endogenous HCG in the stimulation cycle, is 
another option for prevention. It has been reported that this procedure reduces the severity of 
OHSS, but not the incidence (23). However, a lower incidence of OHSS after clyopreservation of 
all embryos, with good results of subsequcnt thaw cyeles, has becn described (21). 
Tbe use of progesteronc instead of HCG for luteal support is advised to reducc the risk for 
OHSS (19). However, support with progesterone during thc luteal phasc does not prevent OHSS. 
Nowadays, in our programme progesterone (200 mg vaginally twice daily; Progestan t ; Organon) 
is routinely used when ~15 follicles arc aspirated during oocyte retrieval. Despite this, severe 
OHSS developed in 8 cases. 
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In an effort to prevent third space fluid accumulation, Asch et a1. (36) treated high risk 
subjects for Ol-ISS \vith albumin so as to increase the senllll oncotic pressure, and possibly reverse 
the leakage of fluids from the intravascular space. The patients recieved 50 g of human albumin 
i. v. at the time of oocyte retrieval. Among 36 high risk patients no case of severe OHSS occurred. 
In a prospective placebo-controlled study, Shoham et al. (37) confirmed the possible role of the 
administration of albumin in the prevention of OHSS. The authors postulated that apmt from the 
plasma expanding effect of albumin, the binding and transpOit properties of human albumin may 
play the main role in the prevention of severe OHSS by binding eeliain factor(s) that are possibly 
members of the renin-angiotensin cascade. However, absolute prevention of OHSS is not 
achieved with albumin administration. Two cases of OHSS occUlTing despite the administration 
of albumin have been described (38). 
The key to prevention of OHSS is early identification of the patients at risk. To increase the 
predictability of OHSS, Delvigne et al. (39) developed a formula for pre-oocyte retrieval 
conditions in a multiple discriminant analysis. A prediction rate for the development of moderate 
or severe OHSS of 76.1 % with a false-negative rate of I S.I % was found. The use of this formula 
calls for an intensive and expensive monitoring procedure and can not prevent OI-ISS ill all cases. 
Management of OHSS 
Once OHSS develops, treatment should be aimed at prevention of serious complications, relief of 
symptoms, and shortening of hospital stay. The treatment of individual patients with OHSS varies 
according to its severity. Patients with moderate OHSS can be kept under surveillance as 
outpatients, cases of severe OHSS should be admitted. The patient should be carefully examined 
and the circulatory condition assesscd. Vaginal examination is to be avoided because of the risk of 
injury to the ovaries. The ovaries should be screened by ultrasonography and the presence of 
ascites and pleural effusion noted. Basic laboratolY investigations like full blood count, serum 
electrolytes and renal function tests should be calTied out. The main line of treatment is to correct 
the circulatOlY volume and the electrolyte imbalance, which will improve the renal perfusion and 
prevent coagulation disorders. Colloidal plasma expanders such as dextran or albumin can be used 
to cOlTecl the hypovolemia. The hematocrit can serve as a guide during the treatment of the 
syndrome. Recording of the fluid balance is important, the urinary output must be carefully 
monitored. The use of heparin should be considered in severe OHSS in view of the risk of 
coagulopathy due to hemoconcentration. \Ve used heparin 5000 IU hvice daily for prophylactic 
reasons in 8 out of 18 cases of severe OHSS. Paracentesis is indicated when serious abdominal 
discomfort or breathing difficulties are caused by extensive ascites (17). Five of our patients 
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underwent abdominal paracentesis with marked relief of symptoms. To avoid injUly to the 
enlarged ovaries, drainage of ascites may be performed via the transvaginal route under 
ultrasound guidance (20). A marked positive effect of paracentesis on the diuresis has been 
reported (16, 20). One of our patients had an extensive pleural effusion for which bilateral 
thoraea! drainage was necessmy. Remarkably, in this patient only a small amount of ascites was 
found. Hydrothorax has been described by others as the only extra-ovarian manifestation of 
OHSS (40). 
As prostaglandins have been suggested to be important mediators of the increased vascular 
permeability in OHSS, prostaglandin synthetase inhibitors, like indomethacin, have been used for 
the treatment of the syndrome (4). However, Pride et a!. (14), found no effect of the usc of 
indomethacin on ascites formation in animal experiments. Balasch et al. (41) reported a case of 
severe OHSS complicated by prcrenal oliguria and liver dysfunction due to indomethacin therapy. 
In view of the doubtful benefit of therapy with prostaglandin synthetase inhibitors and the 
possible side-effects, these dmgs should not be used for the treatment of OHSS. 
Secondary complications of OHSS 
Although secondary complications of OHSS arc rare, the severe form of OHSS should be 
considered a potentially life-threatening condition. Thromboembolism, acute puhnonRlY failure, 
hypovolemic shock, hepatocellular damage and renal failure (5, 16,27,41-43) are some of the 
complications that have been reported to occur in association with the syndrome. Mozes et a1. (5) 
reported two cases of arterial thromboembolic complications. One patient died after a carotid 
arteriotomy and another one underwent a leg amputation. Cases of deep cerebral venous 
thrombosis as complication of severe OHSS have been described (43). Deep venous thrombosis in 
the absence of signs of hemoconcentration in a patient with a Imv level of antithrombin III was 
reported by Kaaja et al. (44). Hepatocellular damage may occur as a result of high oestrogen 
concentrations (41). Fonnan et al. (27) described a patient with severe OHSS who had a marked 
and prolonged elevation of liver enzymes, declining only after tennination of the pregnancy 
which ended in a spontaneous abortion. 
Among the cases of severe OHSS in our population no major complications occulTed. In one 
case with moderate OHSS a ruptured ovarian cyst with intra-abdominal bleeding was diagnosed 
during a diagnostic laparoscopy for suspected adnexal torsion. Treatment remained conservative 
and the clinical course was uneventful. 
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Adnexal torsion 
Tn the 2495 IVF cycles shldied, adnexal torsion occurred in two cases. In one case a torsion and 
rupture of an ovmy was diagnosed. After unwinding the ovary, suhlring of the rupture, necessary 
because of bleeding, was not possible because the ovarian tissue was too friable. An adnex 
extirpation was carried out. In the other case an ovariectomy \vas carried out because the ovalY 
was considerd too necrotic to justify a conservative approach. 
Adnexal torsion is an infrequent but serious complication of ovarian stimulation and should be 
considered in every patient with complaints of abdominal pain and nausea during or after COHo 
Kemmallll et a1. (45) described 4 cases of adnexal torsion among 648 menotropin-induced 
pregnancies. Ovarian cysts are the main cause of adnexal torsion (46). Therefore the incidence of 
this complication can be expected to be higher among patients with OHSS. Mashiach et al. (47) 
found 15 cases of adnexal torsion in 201 cases ofOHSS, 12 ofwhol11 were pregnant. The authors 
advised unwinding of the ovmy regardless of its morphological appearance. This procedure was 
carried out in II of 12 patients. Tn 3 patients suture of the fllphlred ovmy was performed, is two 
cases ovarian cystectomy was necessmy. Oelsner et al. (48) expanded on these data by revie\ving 
the outcomes of 40 cases of adnexal torsion managed with detorsion only. In 26 cases laparotomy 
was canied out, the remaining 14 \vere managed with operative laparoscopy. The postoperative 
course was uneventful in all cases. In 35 of the 37 patients available for follow-up, a normal ovmy 
with follicular development was noted all ultrasound examination. It appears that the sparing 
approach should be used in the management of adnexal torsion. 
Complications of the transvaginal procedure 
In the population shldied, one serious visceral injury occulTed in 2495 oocyte retrievals as 
reported elsewhere (49). This patient developed signs of appendicitis during the week after the 
IVF procedure. On the eighth day after oocyte retrieval a laparotomy was performed because of 
suspected peritonitis. A perforated appendix was removed. On histological examination the 
appendix showed several punchlre holes. Intra-abdominal vascular injuries did not occur in our 
population. 
Pelvic inflammatory disease (PID) was diagnosed in 6 patients after transvaginal oocyte 
retrieval, giving an incidence of 0.24% for this complication. The diagnosis was established by a 
rise in body temperahlre to >380 C and signs of pelvic peritonitis on physical examination, 
together with an elevated leucocyte count and erythrocyte sedimentation rate. All patients were 
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hospitalized for intravenous antibiotic treatment. In none of the cases a surgical approach ,vas 
neccssmy. The mean duration of hospital admission was 13 days (range 4-21). 
Oocyte retrieval for IVF was initially calTied out by laparoscopy. The complications of this 
procedure wcre related to the anesthesia, pneumoperitoneum and visceral and vascular injurics 
caused by troicar insertion. The transvaginal ultrasound-guided folliele aspiration has replaced the 
laparoscopy nowadays and is used in the transport IVF programme since 1988. This procedure is 
calTied out under local anaesthesia and is less time-consuming. Complications are infrequcnt but 
potentially serious. Pelvic visceral and vascular injuries have been reported (49, 50). Pelvic 
inflammatOlY disease is another potential hazard. Dicker et a1. (51) repm1ed 5 symptomatic 
injuries needing a surgical approach among 3656 ovum pick-ups: 2 patients with ruphlred 
endometriotic cystic masses and 3 cases of intra-abdominal bleeding. A case of infected 
endometriotic cysts sccondary to oocyte aspiration was dcscribed by Yaron et al. (52). 
The risk of pelvic infection was initially seen as a disadvantage of the transvaginal approach. 
To reducc this risk, prcventivc antibiotics and vaginal desinfection have been proposed. (53-55). 
However, the efficacy of these mcasures has not been established. Borlum and Nlaigaard (56) 
reported 2 pelvic infections after 400 vaginal procedures using the semi-sterile technique and 
concluded that acceptable safety is achieved without the use of rigorous disinfection or preventive 
antibiotics. The low incidence of PID in our population supports this. Rep0l1s from large series 
show a low incidence of PID after transvaginal fol1icle aspiration. Ashkenazi et a1. (57) found 28 
cases among 4771 patients, and Bennett et a1. (58) repOIied 18 cases after 2670 procedures, giving 
an incidence of 0.58% and 0.68% respectively. Pelvic infection after IVF treatment is not 
necessarily the result of transvaginal ovum pick-up since a casc of PID as a result of embryo 
transfer in an oocytc donation cycle was reported by Saucr and Paulson (59). 
Ectopic pregnancy 
Thi!ieen out of the 624 pregnancies obtained in the IVF population studied were ectopics, giviog 
an ectopic pregnancy rate of 2.1 %. The incidence of ectopic pregnancy was analyzed according to 
indication for IVF. The results are shown in table 2. In one case an ectopic pregnancy \vas found 
in both fallopian tubes, in two cases an intra-uterine pregnancy was combined with an ectopic 
pregnancy. 
The fIrst pregnancy ever obtaincd aftcr IVF was an ectopic pregnancy (60). The reported 
incidence of cctopic pregnancy aftcr IVF-ET varies frOIll 2 to 11% (61, 62). In view of the 1.2-
1.4% incidcnce for all reported pregnancies (63), the risk for an ectopic pregnancy aftcr IVF is 
105 
high and apparently related to the high incidence of tubal dysfuuction in the IVF population. The 
incidence reported in multi-centric studies is approximately 5% (64, 65). The incidence for 
ectopic pregnancy of 2.1 % in our population is low when compared with results of multi-centric 
studies. No statistically significant higher incidence was found ill the group with tubni 
dysfunction. Conflicting data have been reported on the risk factors associated with ectopic 
pregnancies after IVF. Tubal dysfunctiou appears to be a risk factor (61, 65-69), and preventive 
measures prior to IVF treatment have been proposed. Steptoe et al. (70) advised occlusion of the 
utero-tubal junction on each side if diseased tubes arc present but do not require removal. The 
same suggestion was made by other authors (71). However, Karande et al. (72) reported two 
interstitial pregnancies after IVF, one in a patient with a previous bilateral salpingectomy and the 
other in a patient who had a salpingectomy on the side of the ectopic pregnancy. Apparently, 
during emblYo transfer cmblyos can be flushed into the faiiopian tubes. "'hen tubes are 1101111al, 
the emblYos retu111 to the uterine cavity, simulating the physiological journey of the fertilized 
ovum. This transport may be thwarted when the tubes are dysfunctional. 
Table 2. Rate of Ectopic Pregnancy According to Indication for !VF. 
Indication 
Tubal 
Non-tubal 
Pregnancies 
297 
327 
Ectopic pregnancies 
8 (2.7) * 
5 (1.5) *t 
* Values in parentheses are percentages of pregnancies. 
t p > 0.2 (Xl test) when compared with ectopic pregnancy rate in tubal indications. 
The emblYo transfer technique has been suggested as a factor for the occurrence of ectopics. 
Knutzen et al. (73) injected 40 It! of radiopaque fluid in a mock emblYo transfer and found flux 
into the fallopian hlbcs in 38% of patients. They advised transfer of embryos in a small amount 
(10-20 Ill) of culture fluid in an attempt to prevent reflux. Yovich et al. (74) illserted the delivelY 
catheter 55 nUll only and concluded that this gives an cmblYo transfer to a standard midcavity 
position resulting in H lower ectopic pregnancy rate. 
Evidence exists that ovarian stimulation is associated with an increased incidence of ectopic 
pregnancy (75). McBaill et al. (76) found a high rate of ectopic pregnancy following o\~llation 
induction in the absence of predisposing factors. The authors found an association between the 
occurrence of ectopics and an elevated urinmy oestrogen excretion in the peri-ovulatory phase of 
induced ovulatOlY cycles, and concluded that high oestrogen levels influence tubal cmblYo 
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transport. The use of clomiphene citrate combined with Hl\1G for COH has also been reported to 
be a risk factor (65, 68). Other authors could not confirm this (67,69). 
The incidence of combined intrauterine and extrauterine pregnancy is evidently higher after 
rVF than in spontaneous pregnancies. Rizk et a1. (77) reported a frequency of 1 % in clinical 
pregnancies after IVF. Marcus et al. (78) found 20 heterotopic pregnancies among 2650 clinical 
IVF pregnancies, giving a frequency of 0.75%. A heterotopic pregnancy can give diagnostic 
difficulties (79, 80), and should always be included in the differential diagnosis of symptomatic 
patients with an intrauterine pregnancy after IVF. 
Conclusion 
Our data and those reported in the literahu'c show that IVF treatment, performed under good 
medical and laboratory practice conditions, carries an acceptable risk of complications. Strict 
prevention of OI-ISS is not possible. However, sharp attention to its symptoms and adequate 
treatment can lead to a less severc course of disease. Adnexal torsion occurs infrequently and 
ovariectomy is hardly ever indicated in these cases. Symptomatic visceral lesions and pelvic 
inflammatory disease as a result of follicle aspiration are rare. The risk for an ectopic pregnancy is 
higher when compared with the general population. Despite the low incidence of serious 
complications, counselling of patients on this aspect of IVF treatment is necessary. 
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Chapter 8 
A triplet pregnancy after in vitro fertilization is a 
procedure-related complication that should be prevented by 
replacement of two embryos only 
Fertility and Sterility 1997;67:290-5 
Jan Roestl , Arne M. van Heusden2, Aric Verhoeff\ Harold V.H. IVIous1, Gerard H. Zeilmaker3, 
lDepartmcnt of Obstetrics and Gynaecology, Zuidcrziekenhuis, Rotterdam. lDcpartmen.t of 
Obstetrics and Gynaecology, University Hospital Dijkzigt. 3Departmcnt of Endocrinology and 
Reproduction, Erasmus University. 
SUlllIllury 
To investigate whether the incidence and the outcome of triplet pregnancies after in vitro 
fertilization (IV F) treatment justify limitation of the number of embryos to be transferred to two 
only, the results of all triplet and higherMorder pregnancies occurring ill the transport IVF 
programme at the Zuidcrziekcllhuis were evaluated. The incidence of spontaneous reduction to a 
lower-order pregnancy, and the frequcncy of application of selectivc embryo reduction \vere 
studied. Triplet pregnancies, reaching at least 20 weeks' gestation were compared with 54 
randomly chosen twin pregnancies from the same population, matched for maternal age and 
parity. The prcvalence of triplet pregnancies after replacement of three embryos was evaluated. 
Twcnty-fouf out of 624 consccutive IVF pregnancies, occurring between januari 1989 and 
july 1994, were high-order pregnancies (23 triplets and one quadruplet). Three triplet pregnancies 
spontaneously reduced to twlls. Selective cmbryo reduction was chosen as a therapeutic option 
by two patients with a triplet pregnancy and by the patient with a quadruplet pregnancy, giving an 
acceptance rate for this procedure of 12.5%. Comparison of triplets with twin pregnancies showed 
that more antenatal admissions of longer duration occurred during triplet pregnancies. A higher 
perinatal mortality in the triplet group caused 6 out of 18 patients with a triplet pregnancy to be 
confronted with at least one perinatal death. Triplets \vere born at a lower gestational age, had a 
lower birth weight, and a higher hospital admission rate of longer duration. \Vhen pregnancy 
occurred after replacement of three embryos, the risk of having a triplet pregnancy was 7.5%. 
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Conclusions: The poor obstetric outcome of triplet pregnancies in our population indicates that 
triplet pregnancies after IVF treatment have to be prevented. Selective embryo reduction is 
acceptable for few patients only, and can therefore not be seen as a solution. Replacement of three 
emblYos results in a triplet pregnancy in an unacceptably high percentage. Replacement of two 
embryos only is the prefened mcthod to prevent triplet prcgnancies after IVF. 
Introduction 
Infertily treatment has a considerable influence on the incidence of triplet and higher~order 
pregnancies. About 70% of triplet pregnancies occuning nowadays result from ovulation 
induction or assisted reproductive technologies (ART) (I, 2). The high cost of matemal and 
neonatal care in high~order pregnancies has an effect on the use of health care resources (3) and 
will influence the public opinion about infertility treatment. The repOIied frequency of triplet and 
higher-order pregnancies occurring after IVF treatmcnt is approximately 4-5% (4, 5). 
Incrcased mcdical risks entailed by high-order pregnancics are well documented (6, 7). When 
resulting from an elective procedure like ART, these pregnancies should be considered iatrogenic 
procedure-related complications. Several authors stress the neccessity of avoidance of triplet and 
higher~order pregnancies in IVF programmes. iVledical risks, psychological stress and associated 
costs of these pregnancies were reasons to suggest that more attention should be paid to 
approachcs to infertility that reduce the likelihood of multiple gestation (3, 8, 9). However, the 
incidence of triplet pregnancies after IVF does not decrease (4, 5). Apparently, thc embryo 
replacement policy has not been influenced by the publications mentioned above. For this there 
may be several explanations. In the first place, reported improvements in the outcome of multiple-
gestation prcgnancies (10, II) may calise the perinatal morbidity and mortality in triplet and 
quadruplet pregnancies to be underestimated. Few authors report the obstetric outcome of their 
triplet and quadlllplet IVF pregnancies. Evidence exists however, that high-order gestations ill 
IVF populations are associated with a high perinatal mortality (I2) and neonatal morbidity (6). A 
second reason for risking the occulTence of triplet and quadruplet pregnancies in IVF programmes 
may be the availability of techniques for selective emblYo reduction in high-order pregnancies. 
Although improvements in the techniques for selective foeticide have been reported, the ethical 
aspects of thc procedure are undcr debate and the risk of a total pregnancy loss is still 
considerable. This causes the unacceptability of selective embryo reduction for the majority of 
patients (7, \3). In the third place, the pursuit of high pregnancy rates can lead to replacement of 
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three or more emblyos in IVF programmes. The 1990 results fi'OIll the United States IVF-ET 
Rcgistly show that 7% of the reporting clinics transfer on average morc than five embryos per 
cycle (4). Azelll et al. (14) report the replacement ofsLx or more embryos in patients with repeated 
previous lYF failures. Although evidence exists that replacement of a higher number of embryos 
is associated with higher pregnancy and delivelY rates (4), some authors found that replacement 
of two instead of three good embryos does not decrease the chance of a pregnancy significantly, 
but only decreases the multiple pregnancy rate (8, 9). Replacement Gfmore than two cmbl)'os will 
inevitably lead to high-order pregnancies in some cases. The question is whether the possibly 
higher pregnancy rate outweighs the disadvantages and risks of high-order pregnancies. 
The aim of this study is to investigate whether it is necessary to completely prevent thc 
occurrcnce oftriplct pregnancies in an IVF programme. This is done by evaluating the outcome of 
all triplet pregnancies in our programme. The acceptability of selectivc emblYo reduction for 
patients in case a triplet or quadruplet pregnancy occurs is assessed. The results of IVF treatmcnt 
after replacement of 2, 3 or 4 embryos is evaluated to investigate ,,,It ether pregnancy rates after 
replacement of two emblyos arc acceptable. Finally, tbe risk of inducing a triplet prcgnancy after 
replacement of three embryos is evaluated. 
Materials and methods 
During the period January 1989 to June 1994, 2495 oocyte retrievals for IVF treatment were 
carried out in the transport IVF programme at the Zuiderziekenhuis in Rotterdam. This 
programme, carried out in cooperation with the University Hospital Rotterdam, Dijkzigt, bas been 
described elsewhere (15). Fresh emblYo transfer took place in 2044 cycles, and in 1818 cases 
more than one embryo was available for replacement. Thc llumber of emblYos replaced ranged 
from one to four, depending on the patient's age and the availability and quality of thc emblYos. 
Patients < 35 years of age werc asked to consider replacement of not more than two emblYos so as 
to avoid a triplet pregnancy. The final advice on the number of cmbryos to be replaced ,,,as given 
by the IVF laboratory staff. EmblYo transfer was carried Ollt on the 2nd to 5th day after follicle 
aspiration. The diagnosis triplet or quadl1lplet was made by transvaginal ultrasound examination 
at 7 to 9 weeks' pregnancy. The presence of embryos with heart activity confirmed the diagnosis, 
empty gestational sacs werc not included. The incidence of spontaneous reduction to a lower-
order pregnancy was studied. Patients with a triplet or quadruplet pregnancy were informed about 
the possibility of selective emblYo reduction and wcre refened when they opted for this 
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procedure. Eighteen triplet pregnancies, reaching at least 20 weeks' gestation, were compared 
with 54 twin pregnancies randomly chosen from the same IVF population, matched for maternal 
age and parity. Triplet and twin prcgnancies were compared for complications during pregnancy, 
perinatal mortality and neonatal morbidity. The results of the 1818 embryo transfers with 
replacement of two, three or four embryos were evaluated. The incidence of triplet pregnancy 
among pregnancies obtained after replacement of three embryos, and its relation to age was 
studied. 
A clinical pregnancy was defined by a POSItIve urinary pregnancy test 18 days after oocyte 
retrieval combined with the finding of a gestational sac nvo weeks later. An ongoing pregnancy 
was dermed as an intact pregnancy at 12 \veeks gestational age. StillbiI1h was defined as 
intrauterine death after 20 weeks' gestation. For statistical analysis, Student's t-test was used for 
the difference between two means and the X1 test \vas used to compare the frequencies of 
observations. Thc \Vilcoxon rank sum test \vas used where appropriate. P < 0.05 was taken as 
level of significance. 
Results 
During the Shldy period 624 clinical pregnancies were obtained, 584 after fi·csh emblYo transfer, 
40 after replacement of cryopreserved embryos. Out of these pregnancies 476 were singletons, 
124 twins, 23 triplets and one quadruplet. All 24 high-order pregnancies OCCUlTed after fresh 
emblYo transfer, giving a high order pregnancy rate of 4%. Three patients, 2 with triplets and the 
one with quadl11plets, opted for selective embryo reduction, giving an acceptance rate for this 
procedure of 12.5%. One of these triplets reduced spontaneously to twins before embryo 
reduction was carried out. Selective reduction of one triplet and the quadruplet pregnancy to twin 
pregnancies \vas performcd without complications. Both patients delivered two healthy children at 
36 and 37 weeks' gestation respectively. Spontaneous reduction to twins OCCUlTed in 2 additional 
triplet pregnancies. Out of the remaining 19 patients, one patient had an ab0l1ion at 17 weeks' 
gestation, resulting in a total pregnancy loss. The 18 triplet pregnancies reaching 20 weeks' 
gestation or more were compared with 54 twin pregnancies, randomly chosen from the same 
population, matched for maternal age and parity. Patient characteristics and complications during 
pregnancy are shown in table 1. Seventeen patients with triplet pregnancy were admitted 
antenatally. ROl!tine admissions did not occur, cervix cerclage ,vas not applied in any patient. 
Indications reported were: pregnancy induced hypertension (Pill), premature contractions, 
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premature 11lpture of membranes, maternal exhaustion and growth retardation or intrauterine 
death of one or more children. The admission rate and the number of antenatal hospital days for 
patients expecting triplets was significantly higher when compared with those expecting twins: P 
< 0.0001 and P < 0.01 respectively. A higher incidence was found for PIH in the triplet pregnancy 
group. No statistically significant differences were found for the incidence of premature rupture of 
membranes and the use of intravenous tocolitics for premature contractions in the two groups. All 
triplets werc bOlll before 37 weeks' gestation ,vas reached, 44% of the twins were bonl 
prematurely. 
Table 1. Complications in Triplet and Twin Pregnancies Completing 20 Gcstational Weeks 
Matemal age (y) * 
Primigravid patients t 
Antenatal hospitalization 
Hospital days * 
Pregnancy-induced hypertension (PlH) 
Premature contractions + Lv. tocolytics 
Premature rupture of membranes 
Premature delivery § 
<30 weeks 
31-34 wceks 
35-36 weeks 
* Values are means ± SD. 
t NS, not significant. 
Triplets Twins P valuc 
(IFI8) (IF54) 
32.0 ± 3.2 31.7±3.1 NSt 
17 (94) 51 (94) NS 
17 (94) 19 (35) < 0.0001 
27.8 ± 20.1 12.4 ± 11.5 < 0.01 
6 (33) 3 (6) < 0.01 
7 (39) 10 (19) NS 
1 (6) 4 (7) NS 
18(100) 24 (44) < 0.001 
2 
13 7 
3 16 
t Values in parentheses are percentages. 
§ Delivery before completion of 37 gestational weeks. 
The vital statistics of the pregnancy outcome of the triplet and twin pregnancies are shown in 
table 2. Nine intrauterine deaths, discovcred between 22 and 33 weeks' gestation, occurred in 6 
pregnancies in the triplet group. In one case all 3 children died at 22 ,veeks' gestation on 3 
consecutive days during admission for premahll'e contractions. For all cases no explanation could 
bc found after birth. In both groups 2 early neonatal dcaths occurrcd, all due to complications 
after an early premahlre delivCly. The difference for perinatal mortality between the two groups is 
highly significant: P < 0.000 I. 
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Table 2. Vital Statistics of Pregnancy Outcome of the Triplet Pregnancies Compared with Twin 
Pregnancies. 
Triplets (n ~ 54) Twins (n ~ 108) 
Stillbirt 
Early neonatal death (<: 7 days) 
Late neonatal death (8-28 days) 
Perinatal deaths *i' 
* Values in parentheses are percentages of births. 
t p < 0.0001 for comparison between groups. 
9 
2 
o 
II (20) 
2 
o 
3 (3) 
The neonatal outcome of the live-bom children after triplet or twin pregnancies is shown in 
table 3. A statistically significant difference was found for gestational age and bit1h weight. A 
higher percentage of the triplets were admitted; 87% compared ,vitll 53% of twins. The duration 
of hospital stay for admitted children was significantly longer for triplets compared with twins. 
Table 3. Outcome of Live-Born Infants in Triplet and Twin Pregnancies. 
Triplets (n~45) Twins (n~ 107) 
Gestational age, median days (range) 237 (193-255) 259 (163-283) 
Birth weight (g) * 1830 (720-2670) 2470 (550-3700) 
< 1500 g t 10 (22) 5 (5) 
1500-2499 g t 31 (69) 51 (47.5) 
:> 2500 g t 4 (9) 51 (47.5) 
Hospital admission t 39 (87) 57 (53) 
Hospital stay (d) * 35 (5-59) 18 (2-64) 
Neonatal intensive care unit (NICU) t 4 (9) 2 (4) 
Sepsis t 3 (7) I (I) 
Neonatal mortality t 2 (4) 2 (2) 
* Values are medians with range in parentheses. 
t Values in parentheses are percentages. 
t NS, not significant. 
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P value 
< 0.0001 
< 0.0001 
< 0.001 
< 0.0001 
< 0.05 
<0.05 
NSt 
In the triplet group, admission to the neonatal intensive care unit (NICU) and neonatal sepsis 
occurred more frequent. Convulsions were not seen in the triplet group and occurred in one child 
in the t\vin group. No cases of necrotizing enterocolitis or intraventricular hemorrhage occurred in 
either group. Two infants ill the triplet group, bam at a gestational age of 193 days, had a severe 
respiratory distress syndrome and died 6 days after birth. The 2 neonatal deaths in the twin group 
occurred in twins born at the gestational age of 163 days. Both children died immediately after 
birth and were not admitted to the NICU. The resulting neonatal mortality in the 2 groups is not 
statistically significant. 
Table 4. TVF Results in Relation to Number of Embryos Transferred. 
ET ET ET 
n~2 n~3 n~4 
Number of cycles 732 777 309 
Clinical pregnancies * 220 (30 [27-33]) 241 (31 [28-34]) 99 (32 [26-37]) 
Ongoing pregnancies * 176 (24 [21-27]) 193 (25 [22-28]) 80 (26 [21-31]) 
!\1ultiple pregnancies t 49 (22 [16-28]) 73 (30 [23-35]) 28 (28 [18-37]) 
* Values in parentheses are percentages per ET with 95% confidence interval in brackets. 
t Values in parentheses arc percentages per clinical pregnancy with 95% confidence interval 
in brackets. 
The results of 1818 fresh embryo transfers with 2 or more embryos available, are shown in 
tablc 4. and table 5 shows the results of IVF treatment with replaecment of 3 embryos in three 
different age groups. The incidence of triplet pregnancy among pregnancies obtained after 
replacement of 3 emblYos was 7.5%. In the age group 2': 35 years 4 triplet pregnancies occurred 
among 68 clinical pregnancies. Three of these pregnancies were ongoing, giving a triplet 
pregnancy rate of 6% for ongoing pregnancies. 
Discussion 
The incidence of IVF triplets can be expressed as a percentage of all IVF births, or as a percentage 
of births after transfer of three embryos, in our study 3.8% and 7.5% respectively. In the survey of 
data prcsented by the SART (5) the triplet incidence is 5.4% of all deliveries. It is likely that the 
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triplet incidence in pregnancies resulting from the transfer of three emblYos will be considerably 
higher. Spontaneous reduction appears to playa minor role in the natural course of high- order 
pregnancies in the population studied. Spontaneous embryo reduction to a twin pregnancy 
occurred in 3 out of 23 triplet pregnancies only, giving an incidence of 13% per pregnancy. The 
incidence of spontaneous emblyo reduction in multiple pregnancies reported in the literature 
varies and seems to depend on the inclusion criteria used in the various studies. Manzur et aI. (16) 
counted gestational sacs measuring 2': 5 mill in diameter 011 days 21 to 28 after emblYo transfer, 
and found an incidence of vanishing emblyos in triplet pregnancies of approximately 50%. Other 
authors diagnosed a spontaneous reduction only after disappearance of fOlmerly viewed fetal 
cardiac motion and found an incidence of vanishing triplet of 16% per pregnancy (12) or a 5% 
rate of spontaneous fetal demise for a specific embryo in mUltiple gestation (17). In this study we 
used the same criteria and found spontaneous fetal demise in 3 out of 73 initially viable emblyos, 
giving a rate of 4% per emblYo. 
Table 5. Age of the Patient and Replacement of Three Embryos. 
Age category (years) Total < 30 30-34 2: 35 P value * 
EmblYo transfers no. 777 210 333 234 
Clinical pregnancies t 241 (31.0) 63 (30.0) II 0 (33.0) 68 (29.1) 0.80 
Ongoing pregnancies t 193 (24.8) 52 (24.8) 91 (27.3) 50 (21.4) 0.38 
Multiple pregnancies t 73 (30.3) 22 (34.9) 34 (30.9) 17 (25.0) 0.07 
Twins t 55 (22.8) 17 (27.0) 25 (22.7) 13 (19.1) 0.30 
Triplets t 18 (7.5) 5 (7.9) 9 (8.2) 4 (5.9) 0.62 
* i: test for trend between the three age groups. 
t Values in parentheses are percentages per ET. 
t Values ill parentheses arc percentages per clinical pregnancy. 
Selective embryo reduction as a therapeutic option for high-rank pregnancies is under debate. 
The different terms used for the procedure: selective tennination, selective foeticide or selective 
continuation of pregnancy seem to indicate differences in appreciation. Ethical objections and 
medical risks of the procedure cnn not be ignored. Evans et al. (18) argued that selective 
reduction in high-rank pregnancies is ethically justified because it meets the criterion of least 
harm and most potential good. Though perinatal morbidity and mOlialily arc likely to be 
improved when pregnancies with four or more fetuses are reduced to smaller numbers (19), the 
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advantages of reducing the fetal number in triplet pregnancies are less apparent (7, 20). Reduction 
of triplets to twins gives a fctalloss of 33% by definition. The risk of total pregnancy loss after 
selective embryo reduction is considcrable and appears to Vat)' with the method applied. The 
transabdominal and transcervical selective termination is associated \'lith a total pregnancy loss of 
approximately ] 2%, compared with 5.3% for the early transvaginal emblYo aspiration (21). 
Comparative studies of the outcome of triplet pregnancies managed expectantly or by selective 
embryo reduction to twins have been published. Bollen et a!. (12) repmied that the prcgnancy 
outcome of triplets is improved after selective reduction. A prospective study was carried out by 
Lipitz et a1. (7). The authors reported a satisfactory outcome of pregnancy, defined as the 
discharge home of at least one infant, in 88.2% of the group with reduction to twins and in 74.5% 
of the triplets managed expectantly. However, this difference was not statistically significant. 
\Ve informed our patients about the possibility of selective embryo reduction and about the 
possible risks and bencfits. Only 3 out of 24 patients with a triplet or quadruplet pregnancy opted 
for selective embryo reduction, giving a acceptance rate for this procedure of 12.5%. A report 
from Sweden about multiple fetal reduction showed a comparable low acceptance rate of 14% in 
triplet and higher-order pregnancies (13). Apparently, the cmotional aspccts and the procedure-
related risks of selective embryo reduction make the procedure inacceptable for the majority of 
patients. Therefore, selective embryo reduction can not be seen as the solution \vhen highworder 
pregnancies occur after ART. 
In our population the antenatal admission rate and the duration of admission of patients 
expecting triplets was significantly higher when compared with those expecting twins. All 
patients with a triplet pregnancy delivered before the completion of 37 gestational weeks. Sassoon 
et al. (22) reported pretenn labor as the only antenatal complication occurring significantly more 
often in triplet pregnancies compared with twins. 
The vital statistics of triplets and twins show a high number of stillbirths in the triplet group. 
Six out of 18 patients with a triplet pregnancy \'lere confronted with at least one perinatal death. 
The difference with the control twin population is highly significant. Although the neonatal 
mortality rate is low when compared with other reports, the resulting perinatal mortality is high. 
This finding confirms a report by Bollen et al. (12). Other authors reported better outcomes of 
triplet pregnancies. The perinatal and neonatal mortality rates of 78 triplet pregnancies reported 
by Lipitz et al. (II) were 9311000 and 51/1000 respectively. Newman et at. (10) found a perinatal 
mortality rate of 6.6% in 198 triplet pregnancies. Population differences may be an explanation 
for differences in obstetric olltcome. Only 9% of the patients of Lipitz et at. (II), and 7% of the 
patients of Newman et al. (10), becamc pregnant after IVF. Underwreporting in literature of less 
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favourable results can be another explanation for ftnding a higher perinatal mortality rate in our 
population when compared with other studies. 
The median for gestational age and birthweight of live-born triplets is significantly lower 
\vhen compared with hvins. In our study, gestational age and birthweight of hvins and triplets are 
comparable with data reported by other authors (7, 22), The higher admission rate and longer 
duration of admission of triplets appears to be related to prematurity. Seriolls complications 
during the early neonatal period occurred infrequently in both groups. The neonatal mortality in 
the two groups did not differ significantly. Comparable findings were reported by Sassoon et al. 
(22). Other authors (16) report a high neonatal morbidity requiring complex and expensive 
medical care and prolonged hospitalization. 
Considering the low acceptance rate of selective emblYo reduction and the high perinatal 
mortality in the triplet population studied, it appears that prevention, by replacing a maximum 
number of two emblYos, is the approach to be preferred to solve the high-order pregnancy 
problem in ART. The objection to this approach is a possible 100vering of the pregnancy rate. 
Staessen et al. (8) showed that the pregnancy rate is not significantly affected by replacing two 
emblYos only in cycles with a good IVF prognosis. A good prognosis was defined by the criteria: 
first attempt for lVF, age below 37 years, and good embryo development. Tasdemir et al. (9) 
reported that transfer of two emblYos only does not affect the pregnancy rate as long as one good 
quality embryo is available. In several other studies (23, 24) it \vas shown that elective transfer of 
2 emblyos can lead to a high pregnancy rate. 
In the present Shldy it appeared that 6% of the ongoing pregnancies obtained after replacement 
of three embryos in patients aged 35 years and older were triplets. This risk of a triplet pregnancy 
in older patients is considered unacceptably high and indicates that there is no justification for a 
more liberal replacement policy in higher age groups. Therefore, at present, no more than hvo 
emblYos are replaced in any patient in the IVF programme in Rotterdam. Limitation of the 
number of transferred emblYos increases the need for optimal embryo selection at transfer. 
Prolonged emblYo culture seems to be the method of choice to achieve this (25). With 
replacement of hvo embryos, high costs of prolonged hospitalization and complex and expensive 
medical care needed in high-order pregnancies after ART are avoided. In The Netherlands, where 
health insurances pay the costs of three IVF attemps, resources saved in this way could be llsed to 
offer patients a fourth IVF procedure if needed. This would compensate for the possibly lowcr 
pregnancy rate caused by replacement of two embryos only. 
In conclusion, spontaneolls emblYo reduction plays a minor role in the nahlral course of high-
order pregnancies, and selective embryo reduction is not considered an acceptable therapeutic 
option by the majority of patients with triplet pregnancies. The perinatal mortality ill the triplet 
124 
population studied is high \vhen compared with twin pregnancies. The only good solution for the 
problem of the occurrence of high-order pregnancies in ART is strict limitation of the number of 
embryos to be replaced to two. 
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Chapter 9 
Cumulative pregnancy rate and drop-out of patients in IVF 
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Summary 
The validity of cumulative pregnancy rates is tested by the determination of possible influences of 
selective drop~out of patients with a poor treatment prognosis. A cohort of 1211 patients who had 
a first IVF cycle was followed, and the cumulative pregnancy rate (CPR) after 3 IVF cycles was 
assessed. Cycles of patients who discontinued treatment after failed IVF, and of those who did 110t 
achieve a pregnancy but proceeded to a subsequent cycle were compared for OCCUlTcnce of 
prognosticators of pOOl" treatment outcome: fertilization rate, oocyte yield:S; 2, and replacement of 
< 2 emblYos. The CPR after 3 cycles \vas 55.1%. No differences were found between patients 
who continued treatment and those \vho dropped out. 
Conclusion: Selective drop~out of patients with a poor treatment prognosis \vas not found. 
Therefore, the CPR of 55.1 % after 3 IVF cycles gives a reliable indication of the chance of 
occurrence of a pregnancy for a randomly chosen patient in the population studied. 
Introduction 
Patients should be provided with adequate information about their chances of pregnancy before 
they start TVF treatment. The estimation of the likelihood of pregnancy for couples is often based 
on the pregnancy rate per cycle obtained in a programme. However, sevemlmethods can be used 
to express pregnancy rates (PR) in IVF programmes. The definition of clinical or ongoing 
pregnancy can differ between programmes, and PR can be calculated per stm1ed cycle, per oocyte 
retrieval, or per emblYo transfer. \Vhen informing patients about success rates, a possible 
reduction in PR in successive cycles should be considered. This phenomenon has been reported 
131 
by several authors (I, 2), and is explained as the result of heterogeneity of the patient population 
in tenns of fecundity rate. For a randomly chosen patient each unsuccessful cycle constitutes 
evidence ill favor of low fertility potential. 
The success rate in an IVF programme can also be expressed as a cumulative pregnancy rate 
(CPR). When CPRs are used, the danger exists that unrealistic high success rates will be found. 
Not all patients continue IVF treatment until pregnancy or for a fixed number of attempts. 
Therefore, ,,,hen ePRs are used, assumptions arc made about the probability of OCClllTcnCe of a 
pregnancy for those who discontinue treatment. !vfost authors who report on ePRs assume that 
patients who leave an IVF programme had the same probability of pregnancy as those who 
continued (2, 3). For example, Guziek et aJ. (3) reported a CPR of 100% after 9 rVF cycles in the 
subgroup with tubal infertility in their population, while out of the 394 patients entering the study 
in this subgroup only 105 achieved a pregnancy. It is very likely that those who stopped treatment 
because of poor results in a preceding IVF attempt in tenns of oocyte yield, fCliiiization rate, or 
number of emblyos available for replacement, would have had a lower chance of pregnancy than 
those \'1110 continued. For this reason Stolwijk et ai. (4) advised to consider the reason for 
cessation when calculating the CPR. 
To obtain ePRs for thc transport IVF prograll11llC at the Zuiderziekellhuis, Rotterdam, a 
retrospective cohort study \vas carried out. To tcst the validity of the rates obtained, patients \vho 
left the programme without a pregmmey (drop~outs) were compared with those who continued for 
the OCCUlTencc of prognosticators of poor treatment outcome in the preeeeding £1iled IVF cycle. 
1\'laterials and methods 
Patients who had their first fVF attempt during the period JanualY 1989 - June 1994 were 
included in the Shldy. The consecutive IVF cycles of these patients, until the occurrence of a 
clinical pregnancy, \vith a maximuill of 3 cycles, werc used to calculate the CPR after 3 IVF 
cycles. The patients who did not obtain a clinical pregnancy in the first or second cycle were 
divided in 2 groups: those \vho left thc prograll1lllc (drop~outs), and those who proceeded to a next 
attempt. Thcse two groups were compared for age, and the preceding IVF cycles were compared 
for fertilization rate, and for the OCCUlTencc of prognosticators of poor treatment outcome: oocyte 
yield :s 2, and replacement of < 2 emblYos. 
A clinical pregnancy \vas dcfined by a positive urinary test 18 days after oocyte retrieval 
combined with the finding of a gestational sac 2 wceks later. The results of cryopreservation-thaw 
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cycles were included in this analysis. For statistical analysis X2 test or Shldents' t-test was used 
where appropriate. P < 0.05 was taken as level of significance. 
Results 
DUling the study period 1211 patients entered the IVF programme. The results of this cohort arc 
shown in table 1. A statistically significant decrease in pregnancy rate \vas found with increasing 
cycle number. 
Table 1. IVF Results of the First Three Cycles. 
Attempt Patients PR*t CPR Drop-outs 
I 1211 26.6 26.6 263 
2 624 24.5 44.6 193 
3 280 18.9 55.1 
*Pregnancy rate; percentage clinical pregnancies per oocyte retrieval. 
t p < 0.01 for differences between attempt 1,2 and 3 (X' for trend) 
Characteristics of the first IVF cycle of drop-outs and those who continued are shown in table 
2. 
Table 2 . Characteristics of the First Cycles of Drop-outs versus Those who Continued. 
Drop-outs Continued P value 
Number of patients 263 624 
Age 32.4 ± 4.6 32.3 ± 4.4 NS* 
Fertilization rate 43 % 45 % NS 
Oocytes :s 2 11.4% 12.8 NS 
ET<2 37.3 % 34.2 % NS 
* NS, not significant. 
Characteristics of the second IVF cycle of drop-outs and those who continued are shown in 
table 3. 
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Table 3 Characteristics of the Second Cycles of Drop-outs versus Those who Coutinued. 
Drop-outs Continucd P value 
Number of patients 193 280 
Age 32.4 ± 4.3 32.7 ± 4.4 NS • 
FC11ilization rate 46% 45 % NS 
Oocytcs S 2 10.8 % !0.8 % NS 
ET<2 39.5 % 35.9 % NS 
* NS, not significant. 
Discussion 
'''hen patients are informed about their chances of pregnancy in IVF treatment, the shortcomings 
of the different methods used to express the success ratcs of IVF programlllcs should bc kept in 
mind. \Vhen the success rate in an IVF progrmllinc is expressed as PR per IVF cycle, a possible 
reduction in PR in successive cycles should be considered. Hershlag et al. (I) reported that the 
probability of achieving a pregnancy declines as the number of unsuccessful cycles increases. 
Using a mathematical model, the authors estimated that 37% of couples will not conceive with 
IVF therapy despite multiple attempts. They therefore questioned the justification of continuing 
IVF treatment beyond a threshold number of cycles. In contrast, Guzick et al. (3) found that 
persistance in IVF call lead to a sllccessful pregnancy for a large proportion of couples. The 
authors reported an approximately constant pregnancy rate of about 15% over repeated cycles. 
The predicted cumulative pregnancy rate after 9 and 12 cycles were 75% and 84% respectively) 
and, consequently, a 98% cure rate was predicted if multiple cycles were pursued. These 
contradictions in rep0l1ed results of different programmes may be explained as the result of 
selection bias. In the first place) different selcction criteria ,vill cause different patient populations 
at intake. Secondly) some programmcs may encourage patients to discontinue treatment after poor 
performance in the previous IVF cycle, whereas other programmes might encourage these patients 
to proceed to a next attempt. 
Haan et a1. (5) used pre-treatment patient characteristics to make a comparison of the 
prognosis for success between 'continuers) and 'quitters', and found no over-representation of 
patients with a poor prognosis in the group of drop-outs. However, disappointing results in terms 
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of low oocyte yield (S 2), low feltilization rate, and replacement of a suboptimal number « 2) of 
embryos in a previous cycle might be more indicative of poor treatment prognosis than 
pretreatment characteristics (6). Selective patient drop-out, and consequently selection bias, can 
be expected when the frequency of occurrence of these prognosticators of poor treatment outcome 
are higher in patients who discontinue treatment after a failed IVF attempt. 
In The Netherlands thc first 3 IVF attempts are paid for by health insurances. Thercfore, for 
patients eligible for IVF treatment in our population, the CPR after 3 IVF cycles is thc most useful 
information before the treatment is started. In this study the CPR after 3 cycles was calculated, 
and previous cycles of those who continued or dropped out after failed first and second IVF 
attempts were compared for prognosticators of poor treatment outcome. No statistically 
significant differences were found between the 2 groups. Despite this, the PR declined 
significantly as the cycle number increased, confirming reports by others about the phenomenon 
of reduction in PR in successive IVF cyclcs (l, 2). 
In conclusion: selective drop-out of patients with a poor treatment prognosis was not found. 
Therefore, the CPR of 55.1 % after 3 IVF cycles found in this study gives a reliable indication of 
the chance of occurrence of a pregnancy for a randomly chosen patient in our population. 
Pregnancy rates decline with increasing cycle number. 
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Summary 
[n the general introduction contentious issues in assisted reproductive technology (ART) arc 
mentioned, and the objectives of this thesis arc explained. The main objectives are: to determine 
the efficacy of a decentralized IVF progumll1c with transpOli and satellite clinics and to further 
develop criteria for acceptance of patients for IVF treatment. Furthermore, to develop a safer 
embryo replacement strategy, and, \"here possible, to touch upon controversial issues in ART. 
The thesis is divided in two parts. In part one the logistical and organizational aspects of the 
IVF programme at the Zuiderzickenhuis, Rotterdam, are studied, and the feasibility of a 
simplitied protocol for monitoring of patients during controlled ovarian hyperstimulation (COE) 
is assessed. Clinical aspects of IVF treatment are studied in part two. This part is divided into 
three separate sections dealing with: aspects of. patient selection for IVF, the occurrence of 
procedure-related complications, and the expression of success rates in 1 VF pogrammes. 
Chapter 1 is an evaluation of the results obtained in a decentralized IVF programme with a 
transport IVF clinic, satellite clinics and a central University IYF lahoratOlY. The treatment results 
obtained in the decentralized programme were compared with those obtained in the university 
IVF centre using the same laboratOlY facilities. Transportation of oocytes after follicle aspiration 
to a cenlrallaboratory, and monitoring of COH by physicians in satellite clinics appeared to have 
no adverse effects 011 the outcome of IVF treatment. In a decentralized programme laboratory 
facilities can be utilized more efficiently. Moreover, a decentralized programme is more 
accessible for patients in peripheral locations. 
Chapter 2 is a prospective study carried out to assess the fcasibility of minimal monitoring 
during COHo In the transport IVF programme studied, monitoring of COH is canied out without 
estradiol assay but with ultrasound measurements only. The monitoring procedure in the transport 
clinic \vas minimized, while the monitoring protocol used in the satellite clinics, where physicians 
monitored their own patients, remained unchanged. In a prospective study minimal monitoring 
appeared to have no adverse effects on the treatment outcome. Si.xty-two percent of cycles at the 
transport clinic were monitored with one ultrasound measurement only. There appears to be no 
need for extensive monitoring during COl-! for IVF. 
Chapter 3 is a revie\v of the literature about the logistical advantages of gonadotrophin-releasing 
hormone agonists (GnRH~a) in IVF. Moreover, the experience with the use of GllRI-I-a in the 
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transport IVF programme is reportcd. During routine use of GnRH-a the short flarc-up protocol 
and the long protocol give comparable clinical results. Both protocols are useful for treatment 
planning and offer important logistical possibilities. In tenns of cost, time and inconvenience for 
patients, the short flare-up protocol seems to be the most appropriate regimen for routine lise. The 
intranasal administration of GnRH-a appears to be equally efficacious when compared with the 
subcutaneous route. 
Chapter 4 reviews the literature about the relation between age and outcome of IYF treatment. 
The patient's age, although an indicator of fecundity, should not be the main parameter for 
acceptance of patients for IVF treatment. Results of prcstimulation tests like the determination of 
basal follicle-stimulating hormone level and the clomiphene citrate stimulation test are more 
useful for counselling of patients before treatment is started. 
Several proposals have been made to improve the trcatment outcome of IVF in older women. 
The administration of higher dosages of gonadotrophins during con and GnRH-a in the flare-up 
regimen has been proposed for "poor responders". Assisted hatching of embryos with a thick zona 
pellucida has been reported to improve the embryo implantation rate. Replacement of higher 
numbers of embryos is seen as an option by some authors. Oocyte donation, although 
controversial in postmenopausal women, is a good alternative for older patients \vho fail to 
cOllcieve \vith their own ooeytes. 
In chapter 5 a retrospective study, calTied out to determine whether age or response to COH is a 
better predictor of IVF outcome in women ;:: 40 years of age, is described. The frequency of 
occunence of a poor ovarian response to COH increased significantly with rising age. Analysis of 
all cycles showed a significant decrease in clinical and ongoing pregnancy rates for women;:: 40. 
Analysis of cycles with a good ovarian response showed no statistically significant difference for 
these parameters behveen \"omen aged 2: 40 and those younger. A logistic regression analysis on 
pregnancy shmved that ovarian response contributed more to the prcdiction of pregnancy than 
age. A strict age limit for acceptance of patients for IVF treatmcnt should therefore not be used. 
Instead, the response to COH can be llsed to select patients likely to have a successful treatment 
outcome. 
Chapter 6 deals \"itb the treatment prognosis after poor fertilization in the first rVF cycle. Total 
fertilization failure and poor fertilization were defincd. The relation betwcen fertilization rate and 
the number of motile sperm cclls/mL semen was evaluated. Three patient groups with different 
semen quality in the first IVF cycle were defmcd. In all groups poor fertilization appeared to have 
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a high chance of reeun-ence in a second IVF cycle. In the population shldied the use of 
intracytoplasmic spenll injection should be considered after poor fertilization in the first IVF 
cycle, cspecially in cases with a small oocyte yicld. 
Chapter 7 is a review of the literature about the occurrence of procedure-related clinical 
complications of IVF treatment. In this chapter the clinical complications \vhich occurred in 2495 
consecutive cycles are reported. Four different complications leading to hospital admission were 
identified: the ovarian hyperstimuiation sydrome, adnexal torsion, pelvic inflanunatOlY disease, 
and ectopic pregnancy. A total number of 51 patients with complications was admitted. It is 
neeessmy to counsel patients for the occurrence of serious procedure-related complications before 
IYF treatment is started. 
In chapter 8 the outcome of all hlgh-order pregnancies obtained in 2495 consecutive IYF cycles 
is described. The occurrence of spontaneous reduction to a lower-order pregnancy, and the 
acceptability of selective emblYo reduction were shldied. nventy-four out of 624 consecutive 
pregnancies were high-order pregnancies (23 triplets and one quadruplet). Eighteen triplet 
pregnancies reached at least 20 weeks' gestation and were compared with 54 randomly chosen 
twin pregnancies from the same population, matched for maternal age and parity. The results of 
IVF treatment after replacement of 2, 3 or 4 emblYos were evaluated, and the chance of 
occurrence of a triplet pregnancy after replacement of 3 embryos was assessed. Selective emblYo 
reduction was chosen as a treatment option by two patients with a triplet pregnancy and by the 
patient with quadruplets, giving an acceptance rate for this procedure of 12.5%. Three triplet 
pregnancies reduced spontaneously to hvins. A high number of perinatal deaths (11/54) was found 
in the triplet group, causing 6 out of 18 couples \yith a triplet pregnancy to be confronted with the 
loss of at least one child. '''hen compared with hYins, tIiplets were bom at a lower gestational age, 
had a 100ver birth weight, and a higher hospital admission rate of longer duration. "'hen a 
pregnancy OCCUlTed after replacement of three emblYos, the risk of having a triplet pregnancy \vas 
7.5%. Replacement of hvo emblYos only gave acceptable treatment results and is the method 
chosen in the IVF programme in Rotterdam to prevent triplet pregnancies. 
In chaptel' 9 the various methods to express the success rates of an IYF programme arc discussed. 
The cumulative pregnancy rate (CPR) after three attempts in the IVF programme studied was 
calculated, and the validity of this CPR was tested by assessing a possible influence of drop-out of 
patients with a poor treatment prognosis. Cycles of patients who discontinued treatment after 
failed IVF and of those \vho did not obtain a pregnancy but proceeded to a subsequent cycle were 
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compared for fertilization rate and for occurrcnce of prognosticators of poor treatment outcome: 
oocyte yield <:: 2 and replacement of < 2 embryos. The CPR after 3 cyclcs was 55.1 %. No 
differenccs were found between patients who continued treatment and those who dropped out. 
Selective drop-out of patients with a poor treatment outcome was not found. Therefore, the CPR 
of 55.1 % after 3 IYF cycles gives a reliable indication of the chance of occurrence of a pregnancy 
for a randomly chosen patient in the population studied. Pregnancy rates decline with increasing 
cycle number. 
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Conclusions 
• Decentralization of IYF treatment with transpOit and satellite clinics has no adverse effects 
on the treatment outcome and offers several advantages to the patients. 
• In most cases the monitoring of controlled ovarian hyperstimulation for IVF can be limited 
to onc ultrasound measurement only. 
• An age limit of 40 years for acceptance of patients for IVF is not justified. 
• Poor fertilization has a high chance of recurrence in a second IYF cycle, ilTcspective of the 
number of motile SpCllll cells/mL semen in the first cycle. 
• In approximately 2% of cases IYF treatment gives procedure-related clinical complications 
leading to hospital admission. 
• Triplet pregnancies after IVF should be prevented by replacement of two embryos only. 
• Cumulative pregnancy rates should be validated by analysis of the treatment performance of 
those who discontinued treatment. 
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Samenvatting 
In de illieiding worden controversieIe ondcrwcrpcll op het gebied van de geassistccrde 
voortplantingstechnickcn gcnocmd en worden de doelstellingcll van dit proefschrift vcnneld. De 
doelstellingcn zijn: Het vaststellen van de uitvoerbaarheid en docItrcffcndheid van cell 
gcdcccntraliseerd IVF programma met transport- en satcllictklinieken. Het verder ontwikkclcn 
van kriteria va or het toclatcn van patiCntcn voor IVF behalldeling en het ontwikkclcn van cell 
veiliger beleid bij het terugplaatsen van emblYo's. Verder zul1en controvcrsiClc onderwcrpen op 
het gcbicd van IVF besprokcn worden. 
Dit proefschrift bestaat nit twee dclcn. In deel 1 worden de logistieke en organisatorische 
aspekten van het IYF programma van het Zuiderziekenhuis en de uitvoerbaarheid van een 
vereenvoudigd protocol voor monitoren tijdcns gecontrolcerde ovariele hyperstimulatie 
bestudeerd. Klinisehe aspeeten van de IVF behandeling worden bestudeerd in deel 2. Dit deel is 
in drie sceties onderverdeeld \vaarin behandeld \vorden: aspekten van seIcctie van patienten voor 
IYF, het v66rkomen van complicaties ten gevolgc van de behandeling, ell de wijzc waarop 
succespercentages in IVF programma's worden weergegeven. 
Hoofdstllk 1 is een evaluatie van de rcsultaten verkregen in een gedecelltralisecrd IVF 
programma met een transport IYFwkliniek, satellietkliniekell en een centraal universitair IVF 
laboratoriulll. De verkregen behandelingsresultaten van het gedeccntraliseerde programma werdcn 
vergeleken met de resultaten vcrkregen in dc universitaire IVF-kliniek. Beide programma's 
\verken samen met hetzelfde IVF-Iaboratorium. Transport van eicellen na eicelpunctie 11aar het 
centrale IVF-Iaboratorium gevolgd door emblyoterugplaatsing in de universitaire IVF-kliniek 
bleck geen nadelige effecten op de uitkomst van dc IVF-behandeling te hebben. In een 
gedecentraliseerd programma kunnen laboratoriumfaciliteiten efficienter benut worden. 
Bovendien is cell gedeeentraliseerd progranuna toeganke-lijker voor patienten die verder van IVF 
klinieken verwijderd Wallen. 
Hoofdstul< 2 is een prospcctieve studie naar de toepasbaarheid een tot eell minimum beperkte 
monitoring procedure tijdens de gecontroleerde ovariele hyperstimulatie. In het transport IVF-
programma werd de ovariele hyperstillmlatie vervolgd door middel van cchoscopisch onderzoek 
zander bepalingen van het oestradiol in het serum. Het protocol voor het vervolgen van de 
ovariele reactie werd in de transport kliniek veranderd met het doel bet aantal echoscopiCn tot eell 
minimum terug te brellgen. Het protocol voor de satellietklinieken, waar artsen de eigell patienten 
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vervolgden. bleef ongewijzigd. In een prospeeticvc vergelijkende studie bleek het nieuwe protocol 
geell Iladelige effecten op de uitkoll1st vall de IVF-bchalldclillg te hebben. Bij 62% vall de eycli 
die in de transport kliniek vervolgd werden bleek een cchoscopie afdoende. Hct intensief 
vervolgen van de ovariele hyperstinllllatie voor IVF blijkt derhalve niet noodzakelijk te zijn. 
Hoofdstuk 3 is een overzicht van de Iiteratuur over de logistieke voordelen van gonadotropine-
releasing hormoon agonisten (GnRH-a) bij IVF, en een evaluatie van het gebmik van GnRI-I-a in 
het transport IVF-programma. Bij routine gebruik van GnRH-a geven het korte flare-up protocol 
en het lange protocol vergelijkbare klinische resultaten. Beide proto collen kunnell gebmikt 
worden voor planning van de behandcling en bieden belangrijke logistieke Illogelijkheden. I-let 
korte flare-up protocol lijkt het meest aangewezcn protocol met het oog op kosten, tijd en 
ongemak voor de patient. Dc intra-nasale toediening van GnRH-a blijkt even goed toepasbaar als 
de subclitanc toediening. 
Hoofdstuk 4 is eell overzicht van de Iiteratuur over de relatie tussen leeftijd en uitkomst van TVF-
behandeling. Hocwel de leeftijd van de patient een roI speelt bij de vruchtbaarheid, dient lecftijd 
niet de belallgrijkste parameter te zijn bij het accepteren vall patiellteo voor IVF. Bepaling van het 
basaal follikel-stimulerend honnoon en de clomifeen citraat stimulatie test zijn betel' bruikbaar 
voor het voorlichten van patienten voor aanvang vall de behandeling. 
Verschillende methoden Zijll voorgesteld om de resultaten van IVF bij oudere patienten te 
verbetcren. De toediening van hoge doseringen gonadotrofines en het gebmik van GnRH-a in het 
flare-up protocol zijn voorgesteld vaal' paticnten met een slechte ovariele reactie tijdens 
gecontroleerde ovariele hyperstimulatie. De terugplaatsing van hogere aantallen embryo's wordt 
door enkele auteurs als een behandelingsmogelijkheid gezien. Eiceldonatie, hoewel contraversieel 
bij postmenopausale vrouwen , is een goed aItematief Vaal' oudere vrouwen met slcchte 
behandelingsresultatcn. 
Hoofdstul{ 5 is eell retrospectieve studie uitgevoerd om te bepalcn of de leeftijd of de ovariele 
reactie op hyperstimuiatie de betere voorspeller is van de uitkomst van IVF-behandeling bij 
vrouwen ouder dan 40 jaar. Een slechte ovariele reactie op gecontroleerde hyperstimulatie wordt 
significant vaker gezien bij audere patienten. Bij een analyse van alle uitgevaerde IVF-
behandelingen wordt een significante daling van het percentage klinische en doorgaande 
zwangerschappen per behandeling gezien bij patienten DudeI' dan 40 jaar. Echter, bij analyse van 
behandelingcn waarbij sprake was van een goede ovariele reactie bleek er voor deze parameters 
geen statistisch significant verschil te bestaan tussen patienten DudeI' en jonger dan 40 jaar. Een 
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logistische regressie analyse voor Z\vangerschap liet eveneens zien dat ovariele reactie op 
hyperstimulatie een hogere voorspeHende waarde heeft dan leeftijd. Een strikte leeftijdsgrens voor 
behandeling met IVF dient dan ook niet gehantcerd te worden. In plaats hiervan kan de ovariele 
reactie op gecontroleerde hyperstimuiatie gebruikt worden om patiCnten met goede vooruitzichten 
op een succesvolle behandeling te selectCl·en. 
Hoofdstui< 6 behandelt de behandelingsprognose na sleehte bevntehting van eieeHen in de eerste 
TVF-cyclus. Falende bevruchting ell slechte bevmchting ,verdcn gedefinieerd. De relatie tussell 
bevruchtingsgraad en het aantal bewegende zaadcel1en/ mi semen werd gcanalyseerd. Drie 
patientengroepen met verschillende semenkwaliteit in de eerste IVF-cyclus werden gedefrnieerd. 
Tn aIle groepen bleek slechte bevlllchting een hoge herhalingskans te hebben in een twcede 
eyelus. In de bestudeerde populatie dient het gebruik van de intra-eytopIasmatisehe spermatozoa 
injectie overwogen te worden l1a slechte bcvruchting in de eerstc IVF-cyclus. Dit geldt vooral 
wanneer sprake is van een k1cine eicelopbrengst. 
Hoofdstuk 7 is een overzicht van de literatuur over het v6orkomen van klinische complicaties 
gerelateerd aan de I VF -behandeling. In dit hoofdstuk worden tevens de kIinisehe eomplieaties die 
zich voordeden bij 2495 opeenvolgcnde cycli in het transport IVF programma beschreven. Hierbij 
was sprake van vier verschillende complicaties leidend tot ziekenhuisopname: het ovarieel 
hyperstimulatiesyndrootH) steeldraai van een adnex) salpingitis en extra-uteriene graviditeit. Een 
totaal aantal van 51 patienten werd met complicaties opgenoll1en. Het is aangewezen patienten 
voor te lichten over het voorkomen van emstige complicaties van IVF voor aanvang van de 
behandeling. 
Hoofdstuk 8 beschrijft de uitkomst van aBe drie- en vierlingzwangerschappen ontstaan in 2495 
opeenvolgende IYF-behandelingen. Het v66rkomen van spontane reductie tot eell twee- of 
eenlingzwangerschap, en acceptatic van selcctieve embryo reductic werden beshldeerd. Van de 
624 verkregen zwallgcrscbappen bleken er 23 een drielingzwangerschap te zijn) ccmnaal was 
sprake van eell vicrling. Sclectieve cmbryoreductie werd door twee paticnten met cen 
drielingzwangerschap ell door de patient met de vierling vcrkozen als bebandelingsl11ogelijkheid, 
en wcrd dus door slechts 12.5% van de patienten geaccepteerd. Spolltane reductic naar eell 
tweclillgzwangerschap kwam va or bij 3 van de drielingcn. De 18 drielingcn die een 
zwangerschapsduur van 20 of meer weken bereiktcn werdcn vergelcken met 54 tweelingen, 
willekeurig gekozen uit dezelfde populatie, velgelijkbaar voor \Vat betreft leeftijd en paritei!. De 
resultaten van IYF-behandeling na terugplaatsing van 2, 3 of 4 cmblYo)s) en de kans op eell 
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drielingzwangerschap na terugplaatsen van 3 embryo's werden geanalyseerd. Een hoge perinatale 
sterfte werd gevonden in de groep drielingen (II/54). Vall de 18 paren met eell 
drielingzwangerschap werden er 6 geconfronteerd met het verlies van tenmillste ccn kind. In 
vergelijking met tweelingen werden drielingen vroeger geboren, hadden zij een lager 
geboortegewicht, en \verden de patienten en de killderen vaker en hmgduriger opgenomen. Een 
z\vangerschap na terugplaatsen van 3 embryo's bleek in 7.5% van de gevallen een 
drielingzwangerschap te Zijll. Terugplaatsen vall slechts 2 embryo's bleek acceptabele 
behandelingsresultaten te geven, en is het in het IVF-programma in Rotterdam gekozen beleid om 
drielingzwangerschappen te voorkomen. 
In hoofdstllk 9 worden de verschillende methodes om de succespercentages van een IVF-
programma weer te geven besproken. De eUlllulatieve kans op zwangerschap na drie pogingen in 
het transport IVF-programma werd berekend. Onderzocht werd of deze cumulatieve kans 
beinvloed \verd doordat relatief veel patienten met een slechte behalldeiillgprognose het 
programma verlieten. Cycli van patienten die l1a een mislukte poging stopten met IVF werden 
vergcleken met cycH van patienten die doorgingen met de behandcling. Vergeleken werden de 
bevlllehtingsgraad cn de frequentie van v66rkomen van voorspellers van slechte uitkomst vall de 
bchandeling: eicelopbrcngst ::; 2 en terugplaatsing vall < 2 embryo's. De cumulatieve 
zwangcrschapskans na drie cycli was 55.1 %. PatiCnten die stopten met de behandeling en zij die 
doorgingcn verschildcll niet statistisch significant voor genocmde parameters. De cUll1ulatieve 
zwangerschapskans van 55.1 % na drie cycli gceft derhalve een bctromvbare indicatie van de kans 
op zwangerschap voor een willekeurig gekozen patient uit de bestudccrde populatie. De kans op 
zwangerschap bleek af te nemen in volgende cycli. 
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Conclusies 
• Deccntralisatie van cell IVF programma met transport- en satellietklinieken heeft gecn 
nadelig effect op de uitkomst van de behandcling en biedt de patienten verschillendc 
voordelcn. 
• In de mecste gevallcn kan het monitorcn van de gccontrolecrde ovarieIc hyperstillluiatie voor 
IVF beperkt worden tot s!cehts een echoscopie. 
• Ecn leeftijdslimiet van 40 jaar voor dcelname aan IVF-behandeling is illet gerechtvaardigd. 
• Slechte bevruehting heeft een hoge kans op herhaling in een tweede IVF eye Ius onafuankelijk 
van het aantal bewcgcnde zaadcellen per Ill! semen in de ccrste cyclus. 
• In ongeveer 2% van de gevallen geeft IVF-behandeling klinische complicaties leidend tot 
ziekenhuisopname. 
• Drielingzwangerschappen na IVF dicnen voorkomcll te worden door het terugplaatsen van 
slechts twee embryo's. 
• De geldigheid van de cumulatieve zW8ngerschapskans dient getest te worden door cen 
analyse van de rcsultaten van de patienten die stopten met de behandeling. 
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